Abstract 0
Anti-CD20 antibodies[phsu imft aapp]||react with||CD20[lbpr horm lbtr phsu orch imft aapp]	antibodies[phsu imft aapp]||react with||CD20[lbpr horm lbtr phsu orch imft aapp]	
It[ftcn inpr hlca]||has||has reported[ftcn inpr hlca]	
we[ftcn]||investigated||investigate[ftcn]	we[ftcn]||investigated||To investigate[ftcn]	we[ftcn]||investigate||efficacy of third dose[clna resa qnco qlco]	we[ftcn]||investigated||serum IgG antibody titers[bacs fndg lbpr lbtr imft aapp]	


improving seroconversion rate[fndg acty qlco npop qnco]||is in||patients treated with anti-CD20 antibody[phsu imft aapp topp]	third dose[clna topp qnco]||is effective in||improving seroconversion rate[fndg acty qlco npop qnco]	third dose[clna topp qnco]||is effective in||improving seroconversion rate in patients[fndg acty qlco npop qnco]	third dose[clna topp qnco]||is effective in||seroconversion rate in patients treated with anti-CD20 antibody[phsu imft aapp topp]	

Abstract 1
Forecast intervals[inpr patf tmco]||have||have overconfident[inbe]	Forecast intervals[inpr patf tmco]||have||have long overconfident[inbe]	

main cause[fndg qlco ftcn cnce clna]||lies for||uncertainty quantification[fndg qnco]	main cause[fndg qlco ftcn cnce clna]||lies in||misapplication of textbook methods[mnob inpr ftcn]	cause[fndg qlco ftcn cnce clna]||lies for||uncertainty quantification[fndg qnco]	cause[fndg qlco ftcn cnce clna]||lies in||misapplication of textbook methods[mnob inpr ftcn]	
solution[sbst bodm]||obtain||valid interval coverages[inpr tmco qlco idcn ftcn]	solution[sbst bodm]||obtain||interval coverages[inpr tmco qlco idcn ftcn]	solution[sbst bodm]||lies||obtain[ftcn acty]	solution[sbst bodm]||lies in||creative use of predictive tail probabilities[ftcn qnco bpoc qlco]	


Abstract 2
COVAX program[phsu inpr ftcn orch cnce]||aims||provide[acty]	COVAX program[phsu inpr ftcn orch cnce]||provide||global equitable access to life saving vaccines[spco inpr qlco idcn mcha]	COVAX program[phsu inpr ftcn orch cnce]||provide||global equitable access to saving vaccines[spco inpr qlco idcn mcha]	COVAX program[phsu inpr ftcn orch cnce]||provide||equitable access to life saving vaccines[spco inpr qlco idcn mcha]	
vaccine protectionism[phsu orgt qlco imft aapp]||However has limited||progress towards vaccine sharing goals[fndg phsu inpr socb ftcn imft aapp]	vaccine protectionism[phsu orgt qlco imft aapp]||has limited||progress towards vaccine sharing goals[fndg phsu inpr socb ftcn imft aapp]	vaccine protectionism[phsu orgt qlco imft aapp]||However has limited||progress[fndg phsu inpr socb ftcn imft aapp]	vaccine protectionism[phsu orgt qlco imft aapp]||has limited||progress[fndg phsu inpr socb ftcn imft aapp]	
population[lbpr inpr tmco popg gngm rcpt aapp qnco]||is in||Africa[geoa]	
two nation epidemic model[cnce inpr clna phpr]||evaluate given||selfish objectivein[inpr idcn]	two nation epidemic model[cnce inpr clna phpr]||evaluate policies given||selfish objectivein[inpr idcn]	we[ftcn inpr]||use||evaluate given selfish objectivein[inpr idcn]	two nation epidemic model[cnce inpr clna phpr]||evaluate given||objectivein[inpr idcn]	
we[socb]||find||selfish objective[inpr idcn qlco]	we[socb]||find||objective[inpr idcn qlco]	we[socb]||find objective Despite||selfish objective[inpr idcn qlco]	we[socb]||find Despite||selfish objective[inpr idcn qlco]	
intensity[phpr ftcn qlco]||sharing||vaccine stockpile[phsu imft aapp]	sharing[socb]||reduces intensity in||donor nation[fndg orgt popg]	sharing[socb]||reduces||intensity of outbreaks[phpr ftcn qlco]	sharing[socb]||reduces in||donor nation[fndg orgt popg]	
effect[fndg qlco]||is intensified||as vaccination rates decrease[acty topp qnco]	effect[fndg qlco]||is intensified||vaccination rates decrease[acty topp qnco]	effect[fndg qlco]||is||intensified[acty topp qnco]	

reducing fatalities[fndg clna qlco]||is in||donor nation[fndg orgt popg]	fatalities[fndg clna qlco]||is in||donor nation[fndg orgt popg]	
findings[ftcn inpr clna]||provide||share with other nations[socb orgt]	findings[ftcn inpr clna]||provide||rationale for nations[orgt idcn]	findings[ftcn inpr clna]||provide||to share with other nations[socb orgt]	findings[ftcn inpr clna]||provide||share with nations[socb orgt]	

Abstract 3
transmission[fndg inpr patf tmco qlco idcn npop]||is often seasonal In||malaria endemic regions[lbpr geoa spco dsyn ftcn]	transmission[fndg inpr patf tmco qlco idcn npop]||is seasonal In||malaria endemic regions[lbpr geoa spco dsyn ftcn]	transmission[fndg inpr patf tmco qlco idcn npop]||is often seasonal with||very low transmission[fndg inpr patf qlco tmco idcn npop qnco]	transmission[fndg inpr patf tmco qlco idcn npop]||is often seasonal In||malaria regions[lbpr geoa spco dsyn ftcn]	
prolonged carriage[ftcn fndg euka tmco]||are thought||seed[cnce plnt lbpr qnco]	Parasites[ftcn fndg euka]||survive||dry season[ftcn fndg euka]	Parasites[ftcn fndg euka]||survive||season[ftcn fndg euka]	prolonged carriage[ftcn fndg euka tmco]||are thought||seed in next transmission season[spco patf tmco]	
We[ftcn inpr]||use||combination of mathematical simulations[fndg phob qlco resa ocdi]	We[ftcn inpr]||use||combination of simulations[fndg phob qlco resa ocdi]	We[ftcn inpr]||use to||dry season carriers[npop qlco fndg tmco]	We[ftcn inpr]||use to||season carriers[npop qlco fndg tmco]	
dry season carriage[npop qlco tmco]||is more likely in||oldest[qnco]	season carriage[npop qlco tmco]||is more likely in||oldest[qnco]	dry season carriage[npop qlco tmco]||is likely in||oldest[qnco]	season carriage[npop qlco tmco]||is likely in||oldest[qnco]	
carriers[fndg]||experience||higher biting rate at beginning of next transmission season[acty phsf spco patf tmco qlco inpo idcn npop qnco]	carriers[fndg]||experience||higher biting rate at beginning of transmission season[acty phsf spco patf tmco qlco inpo idcn npop qnco]	carriers[fndg]||experience||biting rate at beginning of next transmission season[acty phsf spco patf tmco qlco inpo idcn npop qnco]	carriers[fndg]||experience||biting rate at beginning of transmission season[acty phsf spco patf tmco qlco inpo idcn npop qnco]	
exposed individuals[grup popg qlco]||is in||community[grup popg qlco]	

Abstract 4
we[idcn]||have constructed||Mathematical model for transmission dynamics of TB[npop inpr patf idcn]	we[idcn]||have constructed||Mathematical model for transmission dynamics[npop inpr patf idcn]	we[idcn]||have constructed||Mathematical model[npop inpr patf idcn]	we[idcn]||have constructed In||work[ocac]	
solutions[sbst]||are||positive[qlco fndg comd qnco]	Feasibility[qlco]||is||established[qlco]	Mathematical model[inpr patf dsyn idcn npop]||is||well posed[mnob spco fndg qlco]	Mathematical model[inpr patf dsyn idcn npop]||is||posed[mnob spco fndg qlco]	
basic reproduction number R0[inpr qnco]||is||computed[lbpr acty]	reproduction number R0[inpr qnco]||is||computed[lbpr acty]	equilibrium DFE[ftcn fndg sosy qlco]||is||also determined[inpr qnco]	equilibrium DFE[ftcn fndg sosy qlco]||is||determined[lbpr acty]	
Sensitivity analysis[mnob fndg lbpr inpr patf phpr qlco resa ftcn menp qnco]||find||model parameters[fndg cnce inpr clna]	Sensitivity analysis[mnob fndg lbpr inpr patf phpr qlco resa ftcn menp qnco]||is conducted||find[fndg]	Sensitivity analysis[mnob fndg lbpr inpr patf phpr qlco resa ftcn menp qnco]||is conducted||to find[fndg]	Sensitivity analysis[mnob fndg lbpr inpr patf phpr qlco resa ftcn menp qnco]||is||conducted[bhvr]	
TB[inpr patf dsyn idcn npop]||induced||death d[fndg orgf inpr]	Mathematical model[inpr patf dsyn idcn npop]||was observed through||sensitivity analysis[fndg lbpr patf phpr qlco resa ftcn menp qnco]	high impact[fndg inpr qlco gngm idcn]||varies inversely with||R0[inpr]	high impact[fndg inpr qlco gngm idcn]||varies with||R0[inpr]	
simulation[fndg inpr resa cnce mcha clna]||was||performed[ftcn]	Graphical simulation[fndg inpr resa cnce mcha clna]||was||performed[ftcn]	
Graphical simulation[fndg inpr resa cnce mcha clna]||was||observed[ftcn]	model parameters[fndg inpr resa cnce mcha clna]||are directly proportional to||reproduction numberR0[ftcn orgf mnob qlco]	simulation[fndg inpr resa cnce mcha clna]||was||observed[ftcn]	model parameters[fndg inpr resa cnce mcha clna]||are proportional to||reproduction numberR0[ftcn orgf mnob qlco]	
basic reproduction number R0[inpr qnco]||is decreasing function of||recovery rate gamma[fndg acty inpr sosy npop qnco]	reproduction number R0[inpr qnco]||is decreasing function of||recovery rate gamma[fndg acty inpr sosy npop qnco]	basic reproduction number R0[inpr qnco]||is function of||recovery rate gamma[fndg acty inpr sosy npop qnco]	Graphical simulation[fndg inpr resa cnce mcha clna]||is||observed[ftcn]	

Abstract 5
exploitation affects[fndg orga bhvr orgf clna]||is||characterized[acty]	Trafficking affects[celf]||is||characterized[acty]	exploitation[fndg orga bhvr orgf clna]||Trafficking for||sex[fndg orga bhvr orgf clna]	Trafficking exploitation affects[fndg orga bhvr orgf clna]||is||characterized[acty]	

Our objective[inpr qlco]||was examine||extent[humn]	

dataset[inpr]||contain||3,967 instances of 2018 new ICD 10 codes[inpr lang qlco idcn qnco]	dataset[inpr]||contain||3,967 instances of 2018 ICD 10 codes[inpr lang qlco idcn qnco]	dataset[inpr]||was found||contain[ftcn acty]	dataset[inpr]||was found||to contain[ftcn acty]	
new ICD 10 codes[inpr lang qnco qlco]||admitting||diagnosis[fndg]	new ICD codes[inpr lang qnco qlco]||admitting||diagnosis[fndg]	ICD 10 codes[inpr lang qnco qlco]||admitting||diagnosis[fndg]	ICD codes[inpr lang qnco qlco]||admitting||diagnosis[fndg]	
Regression analysis[inpr lang qnco qlco]||found||2 increase in adoption of 2018 new ICD 10 codes[inpr lang qlco gngm ftcn socb qnco]	Regression analysis[inpr lang qnco qlco]||found||2 increase in adoption of 2018 ICD 10 codes[inpr lang qlco gngm ftcn socb qnco]	Regression analysis[inpr lang qnco qlco]||found||2 increase in adoption[inpr lang qlco gngm ftcn socb qnco]	Regression analysis[inpr lang qnco qlco]||found||2 increase[inpr lang qlco gngm ftcn socb qnco]	
2018 new ICD 10 codes[inpr lang qnco qlco]||were used majority by||1,532 distinct providers[ftcn fndg]	2018 new ICD 10 codes[inpr lang qnco qlco]||were used by||1,532 distinct providers[ftcn fndg]	new ICD 10 codes[inpr lang qnco qlco]||were used majority by||1,532 distinct providers[ftcn fndg]	new ICD 10 codes[inpr lang qnco qlco]||were used by||1,532 distinct providers[ftcn fndg]	
trafficking[celf]||corresponds to||90.1[qnco]	data[medd idcn euka]||contained||2301 patients[podg]	trafficking[celf]||corresponds to||identification of latter patients[hlca]	trafficking[celf]||corresponds to||identification of patients[hlca]	
latter patients[podg]||were||predominantly female[orga qlco popg qnco]	patients[podg]||were||predominantly female[orga qlco popg qnco]	latter patients[podg]||were||female[orga qlco popg qnco]	patients[podg]||were||female[orga qlco popg qnco]	
victims[popg]||were characterized by||high prevalence of mental health conditions[mobd acty qnco]	victims[popg]||were characterized by||prevalence of mental health conditions[mobd acty qnco]	victims[popg]||were characterized by||high prevalence of health conditions[mobd acty qnco]	victims[popg]||were characterized by||prevalence of health conditions[mobd acty qnco]	

2018 new ICD 10 codes[inpr lang qnco qlco]||provide||valuable insights into profiles[ftcn lbpr menp]	2018 new ICD 10 codes[inpr lang qnco qlco]||provide||valuable insights into profiles of victims[ftcn lbpr menp]	new ICD 10 codes[inpr lang qnco qlco]||provide||valuable insights into profiles[ftcn lbpr menp]	2018 new ICD 10 codes[inpr lang qnco qlco]||provide||insights into profiles[ftcn lbpr menp]	
majority[socb popg]||are||likely still[fndg idcn]	majority[socb popg]||diagnosed by||2018 new ICD 10 codes[inpr lang qlco socb qnco]	majority[socb popg]||diagnosed by||2018 ICD 10 codes[inpr lang qlco socb qnco]	majority[socb popg]||are||likely[fndg idcn]	


Abstract 6
have few efforts[orgf qnco]||made cytomorphological categorization of bone marrow cells to||automate[euka]	have efforts[orgf qnco]||made cytomorphological categorization of bone marrow cells to||automate[euka]	There have few efforts[orgf qnco]||made cytomorphological categorization of bone marrow cells to||automate[euka]	There have efforts[orgf qnco]||made cytomorphological categorization of bone marrow cells to||automate[euka]	
deep learning algorithms[mcha inpr]||have||have limited to small number of samples[fndg sbst inpr ftcn bdsu qnco]	deep learning algorithms[mcha inpr]||have||For bone marrow cell categorization have limited[cell clas]	learning algorithms[mcha inpr]||have||have limited to small number of samples[fndg sbst inpr ftcn bdsu qnco]	deep learning algorithms[mcha inpr]||have||have limited to number of samples[fndg sbst inpr ftcn bdsu qnco]	
pipeline[qlco]||classify||bone marrow cells[ftcn cell]	we[qlco]||proposed In||paper[mnob idcn]	pipeline[qlco]||classify despite||limitations[ftcn cell]	pipeline[qlco]||classify bone marrow cells despite||limitations[ftcn cell]	
Data augmentation[fndg euka medd topp idcn]||resolve||class imbalances[cnce inpr sosy clas]	Data augmentation[fndg euka medd topp idcn]||was used throughout||data[qlco aapp inpr enzy]	Data augmentation[fndg euka medd topp idcn]||was||used[cnce]	

proposed CoAtNet model[cnce inpr clna qlco]||used in||pipeline[fndg]	CoAtNet model[cnce inpr clna qlco]||used in||pipeline[fndg]	proposed CoAtNet model used[cnce inpr clna qlco]||was||CoAtNet[cnce inpr clna qlco]	CoAtNet model used[cnce inpr clna qlco]||was||CoAtNet[cnce inpr clna qlco]	
we[tmco]||analyzed||CoAtNet model[cnce inpr clna]	we[tmco]||analyzed||CoAtNet model using[cnce inpr clna]	
proposed CoAtNet model[cnce inpr clna qlco]||evaluating||three models performance for each of distinct morphological classes[inbe clas hlca acty spco inpr cnce]	proposed CoAtNet model[cnce inpr clna qlco]||evaluating||three models performance for each of morphological classes[inbe clas hlca acty spco inpr cnce]	proposed CoAtNet model[cnce inpr clna qlco]||evaluating||three models performance for each of distinct classes[inbe clas hlca acty spco inpr cnce]	CoAtNet model[cnce inpr clna qlco]||evaluating||three models performance for each of distinct morphological classes[inbe clas hlca acty spco inpr cnce]	

Abstract 7
Reagents[irda]||monitor||T cell responses[lbpr lbtr cell orga gngm cnce virs qnco]	Reagents[irda]||monitor based||well characterized epitopes[mnob fndg acty spco qlco idcn ftcn imft]	Reagents[irda]||monitor based||characterized epitopes[mnob fndg acty spco qlco idcn ftcn imft]	Reagents[irda]||monitor to||entire HIV genome[lbpr lbtr cell orga gngm cnce virs qnco]	
T cell responses[lbpr hlca lbtr cell inpr orga qlco virs]||Evaluation of is||importance study[spco inpr qlco]	T cell responses[lbpr hlca lbtr cell inpr orga qlco virs]||Evaluation of is||importance to study[spco inpr qlco]	Evaluation[ftcn dsyn patf]||is of||importance study[spco inpr qlco]	Evaluation[ftcn dsyn patf]||is of||importance to study[spco inpr qlco]	
derived CD4 HIV epitopes[bacs lbpr qlco idcn aapp]||were developed into||Class[fndg inpr clas]	CD4 HIV epitopes[inpr lbpr virs lbtr]||were developed into||Class[fndg inpr clas]	derived CD4 HIV epitopes[bacs lbpr qlco idcn aapp]||were||developed[fndg inpr clas]	CD4 HIV epitopes[inpr lbpr virs lbtr]||were||developed[fndg inpr clas]	
We[orga]||assessed||HIV responses in persons[lbpr lbtr orga popg virs]	We[orga]||assessed||HIV responses in persons with[lbpr lbtr orga popg virs]	We[orga]||assessed||HIV responses[lbpr lbtr orga popg virs]	HIV responses[lbpr lbtr orga popg virs]||is in||persons with[lbpr lbtr orga popg virs]	
We[ftcn]||quantified||HIV specific[bacs lbpr lbtr inpr qlco aapp virs qnco]	We[ftcn]||Using||Activation Induced Marker AIM assay[lbpr qlco gngm idcn ftcn imft aapp clna]	
We[acty]||compared to||commercially available HIV gag peptide pools[lbpr geoa lbtr clas phsu inpr dsyn virs ftcn cnce aapp orch]	We[acty]||compared||Class[fndg inpr clas]	We[acty]||compared to||available HIV gag peptide pools[lbpr geoa lbtr clas phsu inpr dsyn virs ftcn cnce aapp orch]	We[acty]||also compared to||commercially available HIV gag peptide pools[lbpr geoa lbtr clas phsu inpr dsyn virs ftcn cnce aapp orch]	
HIV Class II MP[lbpr clas lbtr inpr cnce virs]||detected||HIV specific CD4 T cells[lbpr lbtr cell sbst inpr qlco bdsu virs qnco]	HIV Class II MP[lbpr clas lbtr inpr cnce virs]||detected in||21/35 60 HIV positive samples[sbst fndg bdsu qnco]	HIV Class II MP[lbpr clas lbtr inpr cnce virs]||detected in||21/35 60 HIV samples[sbst fndg bdsu qnco]	HIV Class II MP[lbpr clas lbtr inpr cnce virs]||detected||CD4 T cells[inpr qlco]	
HIV Class I MP[fndg lbpr clas lbtr inpr cnce virs]||detected||HIV specific CD8 T cells[lbpr lbtr cell sbst inpr qlco gngm bdsu virs qnco]	HIV Class I MP[fndg lbpr clas lbtr inpr cnce virs]||detected in||17/35 48.6 HIV positive samples[sbst fndg bdsu qnco]	HIV Class I MP[fndg lbpr clas lbtr inpr cnce virs]||detected in||17/35 48.6 HIV samples[sbst fndg bdsu qnco]	HIV Class I MP[fndg lbpr clas lbtr inpr cnce virs]||detected||CD8 T cells[lbpr lbtr cell sbst inpr qlco gngm bdsu virs qnco]	
its performance[inbe acty]||is comparable to||other commercially available peptide pools[ftcn phsu aapp geoa]	its performance[inbe acty]||is comparable to||commercially available peptide pools[ftcn phsu aapp geoa]	its performance[inbe acty]||is comparable to||other available peptide pools[ftcn phsu aapp geoa]	its performance[inbe acty]||is comparable to||available peptide pools[ftcn phsu aapp geoa]	
We[fndg topp]||detected||HIV specific[bacs lbpr lbtr inpr qlco aapp virs]	We[fndg topp]||Here detected||HIV specific[bacs lbpr lbtr inpr qlco aapp virs]	CD4[bacs lbpr lbtr inpr qlco aapp virs]||is in||people on cART[mnob bacs lbpr cell orga popg gngm aapp]	

Abstract 8
Food insecurity[fndg]||is highly prevalent among||people with HIV[lbpr virs lbtr]	Food insecurity[fndg]||is prevalent among||people with HIV[lbpr virs lbtr]	Food insecurity[fndg]||is highly prevalent among||people[popg qlco]	Food insecurity[fndg]||is prevalent among||people[popg qlco]	
nutrient poor food assistance programs[edac food inpr grpa qlco idcn ftcn cnce gora qnco]||increase||risk for other chronic diseases[ftcn cnce dsyn idcn]	nutrient food assistance programs[edac food inpr grpa qlco idcn ftcn cnce gora qnco]||increase||risk for other chronic diseases[ftcn cnce dsyn idcn]	
process evaluation[socb inpr hlca qlco]||provide||tailored food assistance to adults[ocac prog aggp qlco]	case study[inpr]||describes||provide[acty]	process evaluation[socb inpr hlca qlco]||provide||tailored food assistance to adults with HIV[ocac prog aggp qlco]	case study[inpr]||describes||process evaluation of novel clinic community partnership[socb inpr hlca qlco]	
semi-structured interviews[phsu inpr qlco resa ftcn orch cnce prog]||is with||program staff[phsu inpr qlco resa ftcn orch cnce prog]	
new program[phsu inpr lang qlco ftcn orch cnce]||enabled||re-engage in HIV care[lbpr lbtr acty inpr virs qnco]	new program[phsu inpr lang qlco ftcn orch cnce]||enabled||to re-engage in HIV care[lbpr lbtr acty inpr virs qnco]	program[phsu inpr lang qlco ftcn orch cnce]||enabled||re-engage in HIV care[lbpr lbtr acty inpr virs qnco]	program[phsu inpr lang qlco ftcn orch cnce]||enabled||to re-engage in HIV care[lbpr lbtr acty inpr virs qnco]	
program implementation reviewed[ocac]||can serve as||roadmap to develop[inpr]	program implementation reviewed[ocac]||can serve as||roadmap develop[inpr]	

Abstract 9
enables model training[menp]||is with||limited datasets[fndg edac inpr qlco ftcn cnce clna]	
use[ftcn aapp inpr enzy]||is in||healthcare[hcro mnob hlca]	
GPT 2[aapp enzy]||investigate||performance of GPT 2[inbe aapp acty enzy]	GPT 2[aapp enzy]||investigate||performance for medical text prediction[inpr idcn]	GPT[aapp enzy]||investigate||performance of GPT 2[inbe aapp acty enzy]	GPT[aapp enzy]||investigate||performance for medical text prediction[inpr idcn]	

model[cnce inpr clna]||tested on||remaining 10[inpr qnco qlco]	model[cnce inpr clna]||validated on||10[qnco]	model[cnce inpr clna]||was||trained[qnco]	
GPT 2 report model performance[inbe acty enzy hlca spco inpr qlco tmco idcn ftcn cnce aapp orgf clna]||is in||terms of next word prediction accuracy[inbe acty enzy hlca spco inpr qlco tmco idcn ftcn cnce aapp orgf clna]	
GPT 2[aapp enzy]||analyze performance on||different types of prediction tokens[inpr qlco idcn cnce clna]	GPT[aapp enzy]||analyze performance on||different types of prediction tokens[inpr qlco idcn cnce clna]	GPT 2[aapp enzy]||analyze performance on||types for categories[inpr]	GPT 2[aapp enzy]||Additionally analyze performance on||different types of prediction tokens[inpr qlco idcn cnce clna]	
GPT 2[aapp enzy]||annotate token by||category[inpr clas]	GPT[aapp enzy]||annotate token by||category[inpr clas]	GPT 2[aapp enzy]||annotate token in||100 randomly sampled notes[diap inpr idcn cnce qnco]	GPT[aapp enzy]||annotate token in||100 randomly sampled notes[diap inpr idcn cnce qnco]	


GPT Neo53[aapp enzy]||performs for||especially names[inpr qlco]	GPT Neo53[aapp enzy]||also performs for||especially names[inpr qlco]	GPT Neo53[aapp enzy]||performs better for||especially names[inpr qlco]	GPT Neo53[aapp enzy]||also performs better for||especially names[inpr qlco]	
pre-trained models[cnce]||have||potential[qlco]	models[inpr]||have||potential[qlco]	
lessons[menp]||suggestions for||future implementations[acty idcn tmco]	
pre-trained models[cnce]||have||potential[qlco]	models[inpr]||have||potential[qlco]	


Abstract 10
majority[socb hlca qnco]||have come from||Asia[geoa]	
paucity[medd idcn euka]||is in||particularly terms of hospitalization co-morbidities[fndg geoa hlca spco inpr tmco gngm idcn orgf qnco]	paucity[medd idcn euka]||is in||terms of hospitalization co-morbidities[fndg geoa hlca spco inpr tmco gngm idcn orgf qnco]	paucity[medd idcn euka]||is in||particularly terms[fndg geoa hlca spco inpr tmco gngm idcn orgf qnco]	paucity[medd idcn euka]||is in||terms[acty]	
study[mnob resa]||set||analyze from 1997 to 2012[qlco]	study[mnob resa]||set||to analyze from 1997 to 2012[qlco]	study[mnob resa]||set||to analyze[qlco aapp inpr enzy]	study[mnob resa]||set forth||analyze from 1997 to 2012[qlco]	
Data[medd idcn euka]||were||analyzed[resa orga]	Data[medd idcn euka]||were analyzed for||age[popg gngm inpr]	
multivariate regression analysis[inpr patf dsyn menp clna qnco]||was performed||assess[acty]	regression analysis[inpr patf dsyn menp clna qnco]||assess||impact of Kawasaki Disease[dsyn gngm qlco]	regression analysis[inpr patf dsyn menp clna qnco]||assess||impact on coronary artery aneurysms[dsyn]	multivariate regression analysis[inpr patf dsyn menp clna qnco]||was performed||to assess[acty]	
multivariate regression analysis[inpr patf dsyn menp clna qnco]||was performed||assess[acty]	regression analysis[inpr patf dsyn menp clna qnco]||assess||impact of Kawasaki Disease[dsyn gngm qlco]	regression analysis[inpr patf dsyn menp clna qnco]||assess||impact on coronary artery aneurysms[dsyn]	multivariate regression analysis[inpr patf dsyn menp clna qnco]||was performed||to assess[acty]	
Patients[podg]||hospitalized for||Kawasaki Disease[dsyn fndg]	
Patients[fndg]||have||congenital heart disease[cgab]	Patients[fndg]||were||less likely[qlco fndg idcn qnco]	Patients[fndg]||is with||Kawasaki Disease[fndg]	Patients[fndg]||have||heart disease[cgab]	
Patients[fndg]||have||congenital heart disease[cgab]	Patients[fndg]||were||less likely[qlco fndg idcn qnco]	Patients[fndg]||is with||Kawasaki Disease[fndg]	Patients[fndg]||have||heart disease[cgab]	
Kawasaki Disease[dsyn]||had||mortality[blor spco acty qnco]	Kawasaki Disease[dsyn]||had||lower mortality[blor spco acty qnco]	


Abstract 11
profile[ftcn acty idcn]||includes||patients with different age groups[aggp podg qlco]	profile[ftcn acty idcn]||includes||patients with age groups[aggp podg qlco]	profile[ftcn acty idcn]||includes||patients[ftcn acty idcn]	profile[ftcn acty idcn]||is in||coronary care units CCU[hcro mnob]	
survival time[clna]||evaluate||association[phpr socb menp qlco]	survival time[clna]||evaluate||association of different factors[ftcn cnce gngm qlco]	survival time[clna]||evaluate||association of factors[phpr socb menp qlco]	survival time[clna]||evaluate on||time[gngm idcn ftcn imft aapp]	

descriptive analysis[inpr]||was||performed[ftcn]	analysis[inpr]||was||performed[ftcn]	
Survival regression[acty clna patf dsyn ftcn menp]||was||modeled[cnce inpr clna]	
p value[qnco]||was defined as||statistically significant[qnco]	p value[qnco]||was defined as||inverted exclamation 0.05[spco inpr ftcn cnce qnco]	p value[qnco]||was defined as||exclamation 0.05[spco inpr ftcn cnce qnco]	p value[qnco]||was defined as||significant[qnco]	
higher average age[orga qnco qlco]||all with||p inverted exclamation 0.00[spco qnco]	higher average age[orga qnco qlco]||was In||patients[podg]	average age[orga qnco qlco]||was In||patients[podg]	higher age[orga qnco qlco]||was In||patients[podg]	
survival probability curve[ftcn spco acty qnco]||reaching||stable value[inpr qnco qlco]	survival probability curve[ftcn spco acty qnco]||presented||higher inclination[tmco qnco qlco]	survival probability curve[ftcn spco acty qnco]||reaching||value[inpr qnco qlco]	survival probability curve[ftcn spco acty qnco]||presented||inclination[tmco qnco qlco]	
hyperpotassemia[fndg]||was shown||independent risk factor for in hospital mortality RR 22[fndg bodm idcn qlco]	hyperpotassemia[fndg]||was shown||to independent risk factor for in hospital mortality RR 22[fndg bodm idcn qlco]	hyperpotassemia[fndg]||was shown||to risk factor for in hospital mortality RR 22[fndg bodm idcn qlco]	hyperpotassemia[fndg]||was shown||risk factor for in hospital mortality RR 22[fndg bodm idcn qlco]	
electronic health record[inpr idcn]||contain||relevant information[idcn qlco]	electronic health record[inpr idcn]||contain||understand[menp]	electronic health record[inpr idcn]||understand||progression of diseases[patf]	electronic health record[inpr idcn]||contain||to understand[menp]	
important topics[ftcn inpr qlco]||enable||research[resa]	important topics related[ftcn inpr qlco]||enable||research[resa]	important topics[ftcn inpr qlco]||enable||research using[resa]	study[mnob resa]||clarify||important topics[ftcn inpr qlco]	
Knowledge[mnob qlco hcro prog qnco]||can allow||management of hospital resources[mnob qlco hcro prog qnco]	Knowledge[mnob qlco hcro prog qnco]||can allow||better management of hospital resources[fndg hlca qlco]	Knowledge[mnob qlco hcro prog qnco]||can allow||better management of physical hospital resources[fndg hlca qlco]	Knowledge[mnob qlco hcro prog qnco]||can allow||better management[fndg hlca qlco]	

Abstract 12

VE studies[hops fndg lbpr geoa]||have found||highly effective[qlco]	VE studies[hops fndg lbpr geoa]||have found||to highly effective[qlco]	clinical trial data[inpr]||have demonstrated||enhanced immunity[phsf acty]	VE studies[hops fndg lbpr geoa]||have found||effective[qlco]	
individuals[popg]||received In||England[geoa]	individuals[popg]||received||ChAdOx1 S booster[bacs phsu nnon topp imft aapp]	individuals[popg]||received ChAdOx1 S booster In||England[geoa]	vaccination[fndg]||was||contraindicated[fndg]	
demographic characteristics[grpa]||were compared to||those[acty]	demographic characteristics[grpa]||were||compared[acty]	characteristics[grpa]||were compared to||those[acty]	characteristics[grpa]||were||compared[acty]	
case control design[fndg lbpr acty irda hlca lbtr inpr medd qlco blor resa ftcn cnce qnco]||estimate||vaccine effectiveness of ChAdOx1 S booster[fndg topp qlco]	case control design[fndg lbpr acty irda hlca lbtr inpr medd qlco blor resa ftcn cnce qnco]||estimate||vaccine effectiveness of ChAdOx1 S booster in England[fndg topp qlco]	case control design[fndg lbpr acty irda hlca lbtr inpr medd qlco blor resa ftcn cnce qnco]||estimate||vaccine effectiveness of ChAdOx1 S booster against disease[fndg topp qlco]	case control design[fndg lbpr acty irda hlca lbtr inpr medd qlco blor resa ftcn cnce qnco]||estimate||vaccine effectiveness of ChAdOx1 S booster against disease in England[fndg topp qlco]	
those[qlco aapp inpr enzy]||were||more likely[fndg idcn qnco]	those[qlco aapp inpr enzy]||were||likely[fndg idcn qnco]	those[qlco aapp inpr enzy]||be||female adjusted odds ratio[orga qlco popg ftcn qnco]	those[qlco aapp inpr enzy]||be||adjusted odds ratio[orga qlco popg ftcn qnco]	

Protection[fndg]||waned to||44.5 22.4[qnco]	
Protection[dsyn inpr patf]||receiving||ChAdOx1 S booster[topp]	Protection[dsyn inpr patf]||peaked as||as 90.9 88.7 to 92.7 for those[qlco aapp inpr enzy]	Protection[dsyn inpr patf]||receiving in||England[geoa hlca]	Protection[dsyn inpr patf]||receiving against||symptomatic disease[ftcn dsyn topp]	
Differences[qlco popg qnco]||boosted in||England[geoa]	Differences[qlco popg qnco]||boosted with||ChAdOx1 S[ftcn food]	Differences[qlco popg qnco]||is in||population[qlco popg qnco]	
study[mnob resa]||supports||use for protection against severe disease[fndg gngm qlco]	study[mnob resa]||supports||use for protection against disease[fndg gngm qlco]	study[mnob resa]||supports||use of ChAdOx1 S booster[ftcn topp]	study[mnob resa]||supports||use for protection against severe disease with COVID 19[fndg gngm qlco]	

Abstract 13
Wuhan[geoa]||China in||2019[geoa]	China[geoa]||is in||2019[geoa]	outbreak[dsyn virs phpr]||has affected||lives[fndg popg]	outbreak[dsyn virs phpr]||has affected globally||lives[fndg popg]	
decision makers strategies[prog menp]||control||pandemic[phpr]	reproduction number[dsyn fndg]||explain||control[ftcn cnce sbst qlco]	reproduction number[dsyn fndg]||explain||decision makers strategies[prog menp]	reproduction number[dsyn fndg]||explain||to control[ftcn cnce sbst qlco]	

Google[idcn]||consider||mobility reductions[fndg]	efficacy values[spco geoa]||is in||region[spco geoa]	
reductions[medd qlco neop ftcn gngm idcn topp npop imft aapp]||reports||ii reduction[medd qlco neop ftcn gngm idcn topp npop imft aapp]	following reductions[medd qlco neop ftcn gngm idcn topp npop imft aapp]||reports||ii reduction[medd qlco neop ftcn gngm idcn topp npop imft aapp]	following reductions[medd qlco neop ftcn gngm idcn topp npop imft aapp]||is in||observed effective reproduction numbers of pandemici reduction[fndg inpr qlco tmco ftcn topp npop]	Google[fndg phsu inpr qlco orch clna]||quantify in||region[clna inpr hlca]	
initial wave[inpr tmco qlco gngm ftcn idcn npop]||is in||countries[geoa]	mobility reduction[fndg spco gngm ftcn qnco]||stave off||wave in countries[geoa]	mobility reduction[fndg spco gngm ftcn qnco]||stave off||initial wave in countries[geoa]	mobility reduction[fndg spco gngm ftcn qnco]||stave off||initial wave[inpr tmco qlco gngm ftcn idcn npop]	
other NPIs[enzy inpr qlco gngm aapp]||have allowed||control of subsequent disease spread[inpr tmco topp qnco]	we[socb]||refer||to as other NPIs have allowed[enzy inpr qlco gngm aapp]	other NPIs[enzy inpr qlco gngm aapp]||have allowed||control of disease spread[inpr tmco topp qnco]	we[socb]||refer||to other NPIs have allowed[enzy inpr qlco gngm aapp]	
methodology propose[inpr idcn]||be applied to||other respiratory diseases[ftcn dsyn]	methodology we propose[inpr idcn]||be applied to||other respiratory diseases[ftcn dsyn]	methodology propose[inpr idcn]||is||novel[inpr qlco]	methodology propose[inpr idcn]||be applied to||respiratory diseases[ftcn dsyn]	

Abstract 14
Several studies[lbpr qnco]||assessed||effect of pre-morbid exposure[fndg genf inpr tmco qlco inpo mamm qnco]	Several studies[lbpr qnco]||assessed to||proton pump inhibitors PPIs on disease course[lbpr moft enzy phsf phsu inpr patf qlco aapp qnco]	Several studies[lbpr qnco]||assessed||effect of exposure[fndg genf inpr tmco qlco inpo mamm qnco]	Several studies[lbpr qnco]||assessed to||proton pump inhibitors PPIs on disease course in COVID 19 patients[lbpr moft enzy phsf phsu inpr patf qlco aapp qnco]	
August 15 2021[diap qlco]||is in||Croatia[geoa]	based matched cohort study[euka tmco qlco dsyn resa popg aggp qnco]||embraced in||adults diagnosed up to August 15 2021[diap qlco]	matched cohort study[euka tmco qlco dsyn resa popg aggp qnco]||embraced in||adults diagnosed up to August 15 2021[diap qlco]	based cohort study[diap qlco]||embraced in||adults diagnosed up to August 15 2021[diap qlco]	
patients[podg]||were classified Considering||over-the-counter OTC availability of PPIs[lbpr phsf phsu ftcn qnco]	patients[podg]||were classified Considering||over-the-counter OTC availability[lbpr phsf phsu ftcn qnco]	patients[podg]||were classified Considering||OTC availability of PPIs[lbpr phsf phsu ftcn qnco]	patients[podg]||were classified Considering||OTC availability[lbpr phsf phsu ftcn qnco]	
Subsets[clas]||were exactly matched in||respect[clas]	Subsets[clas]||were mutually matched in||respect[clas]	Subsets[clas]||were mutually exactly matched in||respect[clas]	Subsets[clas]||were matched in||respect[clas]	
contrast[qlco popg irda]||was considered||most informative for effect of PPIs[fndg lbpr phsf phsu qlco qnco]	contrast[qlco popg irda]||was considered||informative for effect of PPIs[fndg lbpr phsf phsu qlco qnco]	contrast[qlco popg irda]||was considered||most informative for effect[fndg lbpr phsf phsu qlco qnco]	contrast[qlco popg irda]||was considered||informative for effect[fndg lbpr phsf phsu qlco qnco]	
332389[dsyn podg]||were||PPI non-users[lbpr phsf phsu popg ftcn qnco]	18170[dsyn podg]||were||possible users[qlco fndg popg]	332389[dsyn podg]||were||Among 433609 COVID 19 patients PPI non-users[dsyn podg]	
Users[popg]||were||matched to 17334[resa qlco]	Users[popg]||were||matched[resa qlco]	



Abstract 15
study[mnob resa]||aims||investigate[ftcn]	study[mnob resa]||investigate||health related quality of life[idcn]	study[mnob resa]||aims||to investigate[ftcn]	study[mnob resa]||investigate||related quality of life[idcn]	
study[mnob resa]||is cross-sectional study of||COVID 19 survivors[dsyn podg]	study[mnob resa]||is study of||COVID 19 survivors[dsyn podg]	study[mnob resa]||is cross-sectional study of||COVID 19 survivors living[dsyn podg]	study[mnob resa]||is study of||COVID 19 survivors living[dsyn podg]	
Data[medd idcn euka]||were collected from||previously diagnosed COVID 19 participants[diap dsyn popg idcn ftcn]	Data[medd idcn euka]||were collected from||previously diagnosed COVID 19 participants confirmed[diap dsyn popg idcn ftcn]	Data[medd idcn euka]||were collected from||diagnosed COVID 19 participants[diap dsyn popg idcn ftcn]	Data[medd idcn euka]||were collected from||COVID 19 participants confirmed by RT PCR test via door to door interviews in eight different divisions[mnob acty qlco gngm idcn topp orgt qnco]	
Brief[inpr tmco qlco]||COPE||inventory[mnob diap]	Bengali[lang]||translated For||data collection[resa qnco]	Brief Quality QOLBREF questionnaires[inpr]||were||used[fndg]	
data collection period[euka medd tmco resa idcn qnco]||was from||June 2020[bacs lang tmco dsyn gngm aapp]	data collection period[euka medd tmco resa idcn qnco]||was from||June 2020 to March 202[dsyn tmco qnco orga]	Males[dsyn tmco qnco orga]||were||affected by COVID 19 than females 27.62 607[qnco orga]	Males[dsyn tmco qnco orga]||were affected by||COVID 19[ftcn dsyn]	
data collection period[euka medd tmco resa idcn qnco]||was from||June 2020[bacs lang tmco dsyn gngm aapp]	data collection period[euka medd tmco resa idcn qnco]||was from||June 2020 to March 202[dsyn tmco qnco orga]	Males[dsyn tmco qnco orga]||were||affected by COVID 19 than females 27.62 607[qnco orga]	Males[dsyn tmco qnco orga]||were affected by||COVID 19[ftcn dsyn]	
data collection period[euka medd tmco resa idcn qnco]||was from||June 2020[bacs lang tmco dsyn gngm aapp]	data collection period[euka medd tmco resa idcn qnco]||was from||June 2020 to March 202[dsyn tmco qnco orga]	Males[dsyn tmco qnco orga]||were||affected by COVID 19 than females 27.62 607[qnco orga]	Males[dsyn tmco qnco orga]||were affected by||COVID 19[ftcn dsyn]	
data collection period[euka medd tmco resa idcn qnco]||was from||June 2020[bacs lang tmco dsyn gngm aapp]	data collection period[euka medd tmco resa idcn qnco]||was from||June 2020 to March 202[dsyn tmco qnco orga]	Males[dsyn tmco qnco orga]||were||affected by COVID 19 than females 27.62 607[qnco orga]	Males[dsyn tmco qnco orga]||were affected by||COVID 19[ftcn dsyn]	
data collection period[euka medd tmco resa idcn qnco]||was from||June 2020[bacs lang tmco dsyn gngm aapp]	data collection period[euka medd tmco resa idcn qnco]||was from||June 2020 to March 202[dsyn tmco qnco orga]	Males[dsyn tmco qnco orga]||were||affected by COVID 19 than females 27.62 607[qnco orga]	Males[dsyn tmco qnco orga]||were affected by||COVID 19[ftcn dsyn]	
data collection period[euka medd tmco resa idcn qnco]||was from||June 2020[bacs lang tmco dsyn gngm aapp]	data collection period[euka medd tmco resa idcn qnco]||was from||June 2020 to March 202[dsyn tmco qnco orga]	Males[dsyn tmco qnco orga]||were||affected by COVID 19 than females 27.62 607[qnco orga]	Males[dsyn tmco qnco orga]||were affected by||COVID 19[ftcn dsyn]	
data collection period[euka medd tmco resa idcn qnco]||was from||June 2020[bacs lang tmco dsyn gngm aapp]	data collection period[euka medd tmco resa idcn qnco]||was from||June 2020 to March 202[dsyn tmco qnco orga]	Males[dsyn tmco qnco orga]||were||affected by COVID 19 than females 27.62 607[qnco orga]	Males[dsyn tmco qnco orga]||were affected by||COVID 19[ftcn dsyn]	
predominant coping strategy[inbe menp qlco]||coping||followed by problem focused coping[fndg clna tmco]	predominant coping strategy[inbe menp qlco]||coping||focused coping[ftcn spco]	predominant coping strategy[inbe menp qlco]||coping||focused coping with emotion[menp]	predominant coping strategy[inbe menp qlco]||coping||followed by problem focused coping with emotion[fndg clna tmco]	
area[spco geoa]||showed in||participants[popg]	co-morbidities[fndg]||showed in||participants[popg]	Marital status[fndg clna]||showed in||participants[popg]	occupation[ocdi]||showed in||participants[popg]	
study[mnob resa]||represents||real scenario of nationwide health[ftcn inpr idcn qlco]	study[mnob resa]||represents||scenario of nationwide health[ftcn inpr idcn qlco]	study[mnob resa]||represents||real scenario of health[ftcn inpr idcn qlco]	study[mnob resa]||represents||scenario of health[ftcn inpr idcn qlco]	

Abstract 16
Schizophrenia patients[podg mobd]||show||increased disabilities[ftcn fndg qlco]	Schizophrenia patients[podg mobd]||show||disabilities[ftcn fndg qlco]	
magnesium levels[inch bacs fndg acty elii spco phsu]||activation of||interleukin IL -6[bacs phsf phsu gngm imft aapp]	lowered magnesium levels[inch bacs fndg acty elii spco phsu]||activation of||interleukin IL -6[bacs phsf phsu gngm imft aapp]	
study[mnob resa]||assessed||Brief Assessment of Cognition[diap inpr tmco qlco]	study[mnob resa]||assessed||World Health Association QoL instrument Abbreviated version[mnob spco inpr sosy qlco idcn socb menp phpr]	study[mnob resa]||assessed||World Health Association QoL Abbreviated version[mnob spco inpr sosy qlco idcn socb menp phpr]	study[mnob resa]||assessed||World Health Association QoL version[mnob spco inpr sosy qlco idcn socb menp phpr]	
first vector[spco anim nnon qlco idcn qnco]||extracted from||various symptom domains symptomatome[fndg phsu inpr sosy topp ftcn cnce imft clna]	latent vector[spco anim nnon qlco idcn]||extracted from||BACs scores[clna qnco]	latent vector[spco anim nnon qlco idcn]||extracted by||generalized cognitive deterioration G CoDe index[fndg mobd ocac spco diap inpr idcn ftcn qnco]	first vector[spco anim nnon qlco idcn qnco]||extracted from||symptom domains symptomatome[fndg phsu inpr sosy topp ftcn cnce imft clna]	
interleukin IL -6[bacs geoa phsu gngm imft aapp]||helper Th||-17 axis[geoa bpoc enzy elii spco inpr mamm gngm aapp]	
interleukin IL -6[bacs geoa phsu gngm imft aapp]||helper Th||-17 axis[geoa bpoc enzy elii spco inpr mamm gngm aapp]	
latter features[qlco]||are manifestations of||namely social worsening index[fndg diap inpr qlco bhvr idcn ftcn qnco]	latter features[qlco]||are manifestations of||social worsening index[fndg diap inpr qlco bhvr idcn ftcn qnco]	latter features[qlco]||are manifestations of||common core[mnob spco medd inpr qlco ftcn bdsu celc qnco]	latter features[qlco]||are manifestations of||namely worsening index[fndg diap inpr qlco bhvr idcn ftcn qnco]	

Abstract 17
Primary biliary cholangitis PBC[dsyn]||is chronic inflammatory autoimmune disease of||biliary cells[dsyn]	Primary biliary cholangitis PBC[dsyn]||is chronic inflammatory autoimmune disease of||biliary epithelial cells[ftcn cell dsyn patf]	Primary biliary cholangitis PBC[dsyn]||is inflammatory autoimmune disease of||biliary cells[dsyn]	Primary biliary cholangitis PBC[dsyn]||is chronic inflammatory disease of||biliary cells[dsyn]	
aim[mnob resa gngm idcn ftcn imft aapp]||is summarize||imaging features of PBC[dsyn qlco]	aim[mnob resa gngm idcn ftcn imft aapp]||examine||correlation between PBC features[dsyn qlco]	aim[mnob resa gngm idcn ftcn imft aapp]||is summarize||imaging features[dsyn qlco]	aim[mnob resa gngm idcn ftcn imft aapp]||examine||correlation between PBC clinicopathological features[dsyn qlco]	
laboratory data[mnob lbtr hcro ftcn ocdi]||were collected for||patients diagnosed[diap]	laboratory data[mnob lbtr hcro ftcn ocdi]||were||collected[ftcn idcn]	laboratory data[mnob lbtr hcro ftcn ocdi]||were collected for||patients diagnosed for PBC[ftcn dsyn]	laboratory data[mnob lbtr hcro ftcn ocdi]||were collected retrospectively for||patients diagnosed[diap]	
Biochemical data[ftcn fndg]||were compared between||male v.s.[qnco qlco acty orga]	Biochemical data[ftcn fndg]||were compared between||v.s.[qnco qlco acty orga]	data[bmod euka medd idcn ftcn]||were compared between||male v.s.[qnco qlco acty orga]	Biochemical data[ftcn fndg]||were||compared[qnco qlco acty orga]	


273 patients[qlco podg qnco]||diagnosed with||PBC[diap dsyn]	
Non-specific hepatic parenchymal disease[dsyn bpoc]||were||features[spco inpr qlco ftcn blor qnco]	Non-specific parenchymal disease[dsyn bpoc]||were||features[spco inpr qlco ftcn blor qnco]	Non-specific hepatic disease[dsyn bpoc]||were||features[spco inpr qlco ftcn blor qnco]	hepatic parenchymal disease[dsyn bpoc]||were||features[spco inpr qlco ftcn blor qnco]	

LAD[lang]||was reported in||38 47 of PBC[ftcn dsyn inpr hlca]	LAD[lang]||was reported in||38 47 PBC[ftcn dsyn inpr hlca]	LAD[lang]||was||reported[ftcn dsyn inpr hlca]	
imaging characteristics[dsyn fndg qlco]||were||frequently seen[tmco]	imaging characteristics[dsyn fndg qlco]||were frequently seen in||men[qnco]	imaging characteristics[dsyn fndg qlco]||were||more frequently seen[tmco]	imaging characteristics[dsyn fndg qlco]||were seen in||men[qnco]	
AMA negative PBC patients[fndg lbpr pros qlco dsyn podg topp cnce]||had distributions to||AMA positive PBC patients[fndg lbpr pros qlco dsyn podg topp cnce]	negative PBC patients[fndg lbpr pros qlco dsyn podg topp cnce]||had distributions to||AMA positive PBC patients[fndg lbpr pros qlco dsyn podg topp cnce]	AMA negative PBC patients[fndg lbpr pros qlco dsyn podg topp cnce]||had distributions to||PBC patients[fndg lbpr pros qlco dsyn podg topp cnce]	negative PBC patients[fndg lbpr pros qlco dsyn podg topp cnce]||had distributions to||PBC patients[fndg lbpr pros qlco dsyn podg topp cnce]	
PBC[dsyn]||summarized||features of PBC[dsyn qlco]	PBC[dsyn]||summarized||clinicopathological features of PBC[dsyn qlco]	PBC[dsyn]||summarized||features[dsyn qlco]	PBC[dsyn]||summarized||clinicopathological features[dsyn qlco]	
study[mnob resa]||avoid over-testing in||real world practice[inpr qlco popg ftcn menp]	study[mnob resa]||would assist in||diagnosis of PBC[hlca diap inpr qlco dsyn resa ftcn socb]	study[mnob resa]||avoid over-testing in||world practice[inpr qlco popg ftcn menp]	study[mnob resa]||avoid in||real world practice[inpr qlco popg ftcn menp]	

Abstract 18
treatment[tmco]||is with||commonest causative agent[fndg hlca phsu inpr tmco dsyn resa gngm topp ftcn cnce aapp qnco]	
overwhelming number[popg qnco]||associated At||Nakivale refugee camp[spco]	overwhelming number[popg qnco]||often associated At||Nakivale refugee camp[spco]	overwhelming number[popg qnco]||associated with||poor living conditions[inpr grpa qlco]	overwhelming number[popg qnco]||often associated with||poor living conditions[inpr grpa qlco]	
prevalence[qlco dsyn grup qnco]||determine||antimicrobial susceptibility patterns of isolated pathogens[fndg orgm spco idcn ftcn]	prevalence[qlco dsyn grup qnco]||determine||antimicrobial susceptibility patterns of pathogens[fndg orgm spco idcn ftcn]	prevalence[qlco dsyn grup qnco]||determine||susceptibility patterns of isolated pathogens[fndg orgm spco idcn ftcn]	refugees[popg]||is in||Nakivale refugee settlement[popg]	
study[mnob resa]||was||cross-sectional study[resa]	study[mnob resa]||was||cross-sectional[resa]	study[mnob resa]||was||study[mnob resa]	
Prevalence[phsu dsyn gngm aapp qnco]||was||24.1 52/216[phsu dsyn gngm aapp qnco]	
majority 86 39.81[socb popg qnco]||were from||DR Congo[geoa inpr bodm popg prog]	
commonest causative agent[ftcn fndg inpr qnco]||was||Staphylococcus aureus followed by Escherichia coli 21/52 40.38[qnco bact tmco]	commonest causative agent[ftcn fndg inpr qnco]||was||Staphylococcus aureus followed[bacs lbpr qlco dsyn bact qnco]	commonest causative agent[ftcn fndg inpr qnco]||was||Staphylococcus aureus[bacs lbpr qlco dsyn bact qnco]	causative agent[ftcn fndg inpr qnco]||was||Staphylococcus aureus followed by Escherichia coli 21/52 40.38[qnco bact tmco]	
Multidrug[bacs lbtr phsf idcn ftcn]||isolates accounted||for 26.92 14/52[ftcn clna]	Multidrug[bacs lbtr phsf idcn ftcn]||resistant isolates accounted||for 26.92 14/52[ftcn clna]	
30 58[qnco]||were Out||52 Extended Spectrum Beta Lactamase organisms ESBLs[aapp orgm enzy]	30 58[qnco]||were Out||52 Spectrum Beta Lactamase organisms ESBLs[aapp orgm enzy]	
9 30[qnco]||were||non-ESBL producers[ftcn popg]	9 30[qnco]||were||while non-ESBL producers[ftcn popg]	9 30[qnco]||were||producers[popg]	9 30[qnco]||were||while producers[popg]	

prevalence[phsu dsyn gngm aapp qnco]||is high with||Staphylococcus aureus[fndg lbpr inpr qlco dsyn bact idcn]	prevalence[phsu dsyn gngm aapp qnco]||is high as||commonest causes of UTI[phsu inpr dsyn gngm bact ftcn aapp qnco]	prevalence[phsu dsyn gngm aapp qnco]||is||high with Staphylococcus aureus as causes[fndg lbpr inpr qlco dsyn bact idcn]	prevalence[phsu dsyn gngm aapp qnco]||is||high with Staphylococcus aureus as causes of UTI[fndg lbpr inpr qlco dsyn bact idcn]	
high rate[ftcn topp]||treat||UTI[phsu dsyn aapp gngm]	rate[ftcn topp]||treat||UTI[phsu dsyn aapp gngm]	
prevalence[phsu dsyn gngm aapp qnco]||is||high[fndg inpr idcn qlco]	refugees[popg]||is in||Nakivale settlement[popg]	common ESBL genes[fndg]||are||blaTEM[phsu dsyn gngm aapp qnco]	ESBL genes[fndg]||are||blaTEM[phsu dsyn gngm aapp qnco]	

Abstract 19
disruptions[ftcn]||is in||psychological functioning[qlco fndg menp tmco]	related pathological dissociation[bmod fndg mobd qlco inpo ftcn]||is phenomenon||involves[ftcn]	related pathological dissociation[bmod fndg mobd qlco inpo ftcn]||is multidimensional phenomenon||involves[ftcn]	related pathological dissociation[bmod fndg mobd qlco inpo ftcn]||is||multidimensional phenomenon[spco]	
dissociation[mobd]||lacks||synthesized neurobiological model[bmod acty inpr cnce clna]	dissociation[mobd]||lacks||neurobiological model[bmod acty inpr cnce clna]	dissociation[mobd]||lacks||synthesized model[bmod acty inpr cnce clna]	dissociation[mobd]||lacks||model[orga]	
we[fndg]||examined||connectivity of three core neurocognitive networks[mnob fndg spco inpr medd ftcn cnce bdsu celc qnco]	we[fndg]||examined||functional connectivity of three core networks[mnob fndg spco inpr medd ftcn cnce bdsu celc qnco]	we[fndg]||examined||connectivity of three core networks[mnob fndg spco inpr medd ftcn cnce bdsu celc qnco]	we[fndg]||examined||functional connectivity[mnob fndg spco inpr medd ftcn cnce bdsu celc qnco]	
Participants[popg]||varied||levels of pathological dissociation[ftcn bmod dsyn qlco]	91 adult women[popg aggp]||is with||history of childhood trauma[tmco mobd]	Participants[popg]||were||91 adult women[popg aggp]	Participants[popg]||varied||levels of dissociation[ftcn bmod dsyn qlco]	
Participants[popg]||provided||interview data about pathological dissociation[bmod euka mobd medd inpr resa idcn ftcn]	Participants[popg]||provided||interview data[inpr acty]	Participants[popg]||provided||interview data about dissociation[bmod euka mobd medd inpr resa idcn ftcn]	
childhood maltreatment[tmco]||found After||controlling for age[ftcn orga fndg tmco]	PTSD symptom severity[fndg clna mobd]||found After||controlling for age[ftcn orga fndg tmco]	childhood maltreatment[tmco]||found After||controlling[ftcn orga fndg tmco]	PTSD symptom severity[fndg clna mobd]||found After||controlling[ftcn orga fndg tmco]	
we[ftcn idcn]||isolated||unique connectivity markers[ftcn clna qlco]	we[ftcn idcn]||isolated||unique connectivity markers linked[ftcn clna qlco]	we[ftcn idcn]||isolated||connectivity markers[ftcn clna qlco]	we[ftcn idcn]||isolated||connectivity markers linked to depersonalization derealization[inpr mobd]	

treatment engagement[fndg hlca resa topp ftcn cnce]||facilitate||recovery from PTSD[qnco orgf acty mobd]	treatment engagement[fndg hlca resa topp ftcn cnce]||recovery from||PTSD[qnco orgf acty mobd]	treatment engagement[fndg hlca resa topp ftcn cnce]||facilitate||recovery[qnco orgf acty mobd]	neural correlates[ftcn mobd]||may serve as||potential targets treatment engagement facilitate[fndg hlca resa topp ftcn cnce]	
results[hlca qlco]||underscore dissociation assessment as||crucial in care settings[hlca qlco]	results[hlca qlco]||underscore dissociation assessment as||crucial in clinical care settings[hlca qlco]	results[hlca qlco]||underscore dissociation assessment as||crucial[mnob qlco]	results[hlca qlco]||underscore as||crucial in care settings[hlca qlco]	

Abstract 20

18 59y[popg]||completed||cross-sectional web survey[mnob lbpr tmco dsyn resa gngm rcpt aapp]	59y[popg]||completed||cross-sectional web survey[mnob lbpr tmco dsyn resa gngm rcpt aapp]	18 59y[popg]||completed||web survey[mnob lbpr tmco dsyn resa gngm rcpt aapp]	59y[popg]||completed||web survey[mnob lbpr tmco dsyn resa gngm rcpt aapp]	
weighting[hlca qlco qnco orga]||resulted in||quasi-representative population sample[fndg acty sbst popg idcn ftcn bdsu qnco]	based sampling[ftcn resa idcn]||resulted in||quasi-representative population sample[fndg acty sbst popg idcn ftcn bdsu qnco]	weighting[hlca qlco qnco orga]||resulted in||population sample[fndg acty sbst popg idcn ftcn bdsu qnco]	sampling[ftcn resa idcn]||resulted in||quasi-representative population sample[fndg acty sbst popg idcn ftcn bdsu qnco]	
We[acty]||compared||Natsal COVID data[medd idcn euka]	We[acty]||compared||Natsal COVID data with[medd idcn euka]	
Reported need[ftcn inpr hlca]||were||analysed[acty]	unmet need[acty]||were||analysed[acty]	Reported need[ftcn inpr hlca]||were analysed among||participants[popg bhvr]	Reported unmet need[ftcn inpr hlca]||were||analysed[acty]	
Odds ratios[qnco]||adjusted for||age aOR[medd moft qnco]	


Chlamydia[bact]||were||reported by younger participants[grup popg tmco]	men[popg lang]||reporting||sex partnersa[hlca]	men[popg lang]||reporting||same sex partnersa[popg lang hlca qlco]	Chlamydia[bact]||were||commonly reported by younger participants[grup popg tmco]	

differential access[ftcn spco qlco]||continued during||first year of COVID 19 pandemic[qlco tmco dsyn idcn qnco]	differential access[ftcn spco qlco]||continued during||year of COVID 19 pandemic[qlco tmco dsyn idcn qnco]	differential access[ftcn spco qlco]||continued during||first year[mnob resa]	differential access[ftcn spco qlco]||continued during||year[tmco topp qlco]	

large inequalities[qlco qnco]||persisted among||typically those at greatest STI HIV risk[dsyn fndg qnco]	large inequalities[qlco qnco]||persisted among||typically those at STI HIV risk[dsyn fndg qnco]	large inequalities[qlco qnco]||persisted among||those at greatest STI HIV risk[dsyn fndg qnco]	inequalities[qlco qnco]||persisted among||typically those at greatest STI HIV risk[dsyn fndg qnco]	
Key MessagesMany MSM[orch phsu popg]||people of||Black ethnicity[popg qlco]	
Our compared inequalities[ftcn spco acty qlco]||is in||access to key interventions using[clna clas hlca]	
stronger associations[medd lbpr menp qlco]||were During||pandemic Natsal COVID[phpr]	associations[medd lbpr menp qlco]||were During||pandemic Natsal COVID[phpr]	associations[medd lbpr menp qlco]||is with||chlamydia testing for MSM[medd lbpr menp qlco]	associations[medd lbpr menp qlco]||is with||HIV testing for women reporting[popg]	
stronger associations[hlca spco diap qlco resa ftcn blor menp]||were compared during||COVID 19 pandemic[dsyn fndg]	stronger associations[hlca spco diap qlco resa ftcn blor menp]||were during||COVID 19 pandemic[dsyn fndg]	stronger associations[hlca spco diap qlco resa ftcn blor menp]||is with||cervical screening[hlca spco diap qlco resa ftcn blor menp]	stronger associations[hlca spco diap qlco resa ftcn blor menp]||were compared among||smokers[dsyn fndg]	


Abstract 21
based epidemiology[resa]||is||promising approach[spco idcn]	epidemiology[resa]||is||promising approach[spco idcn]	based epidemiology[resa]||is||approach[spco idcn]	epidemiology[resa]||is||promising[spco idcn]	

serial stratified randomized samplings[fndg inpr tmco resa clna]||estimate||prevalence of anti-SARS-CoV-2 antibodies[imft aapp virs qnco]	stratified randomized samplings[fndg inpr tmco resa clna]||estimate||prevalence of anti-SARS-CoV-2 antibodies[imft aapp virs qnco]	serial randomized samplings[fndg inpr tmco resa clna]||estimate||prevalence of anti-SARS-CoV-2 antibodies[imft aapp virs qnco]	serial stratified samplings[fndg inpr tmco resa clna]||estimate||prevalence of anti-SARS-CoV-2 antibodies[imft aapp virs qnco]	
Model analysis[lbpr inpr resa ftcn cnce clna]||revealed||significant temporal differences in epidemic peaksthe average incidence rate[spco qnco tmco qlco resa idcn phpr]	Model analysis[lbpr inpr resa ftcn cnce clna]||revealed||significant differences in epidemic peaksthe average incidence rate[spco qnco tmco qlco resa idcn phpr]	Model analysis[lbpr inpr resa ftcn cnce clna]||revealed||significant temporal differences in epidemic average incidence rate[spco qnco tmco qlco resa idcn phpr]	Model analysis[lbpr inpr resa ftcn cnce clna]||revealed||temporal differences in epidemic peaksthe average incidence rate[spco qnco tmco qlco resa idcn phpr]	
estimated average prevalence rates[acty inpr cnce clna qnco]||correlated with||wastewater correlation[mnob fndg geoa bpoc spco diap inpr qlco eehu qnco]	estimated prevalence rates[acty inpr cnce clna qnco]||correlated with||wastewater correlation[mnob fndg geoa bpoc spco diap inpr qlco eehu qnco]	estimated average prevalence rates[acty inpr cnce clna qnco]||correlated well with||wastewater correlation[mnob fndg geoa bpoc spco diap inpr qlco eehu qnco]	average prevalence rates[acty inpr cnce clna qnco]||correlated with||wastewater correlation[mnob fndg geoa bpoc spco diap inpr qlco eehu qnco]	
weekly unit increase[geoa tmco eehu gngm ftcn virs qnco]||is in||wastewater concentration of SARS CoV 2[geoa tmco eehu gngm ftcn virs qnco]	
health department incidence rates[ftcn qnco hcro]||vastly underestimate||true community incidence[ftcn grup qnco qlco]	health department incidence rates[ftcn qnco hcro]||underestimate||true community incidence[ftcn grup qnco qlco]	health department incidence rates[ftcn qnco hcro]||vastly underestimate||community incidence[ftcn grup qnco qlco]	health department incidence rates[ftcn qnco hcro]||underestimate||community incidence[ftcn grup qnco qlco]	
Research[resa]||reported||case rates[ftcn inpr hlca]	Research[resa]||reported||clinical case rates[mnob fndg acty medd qlco dsyn popg ftcn cnce qnco]	COVID 19 infected individuals[inpr idcn popg]||are biased due||wide range of factors[spco inpr idcn ftcn orch qnco]	COVID 19 infected individuals[inpr idcn popg]||are biased from||access to concerns[spco inpr qlco idcn ftcn]	
alternative[qlco]||support||community monitoring[hlca]	alternative[qlco]||support community monitoring based||fecal shedding of virus[ftcn patf bdsu idcn]	alternative[qlco]||support based||fecal shedding of virus[ftcn patf bdsu idcn]	alternative[qlco]||support community monitoring based||shedding of virus[ftcn patf bdsu idcn]	
We[ftcn inpr mnob ocdi]||examined||English literature[mnob inpr lang qlco popg idcn qnco]	We[ftcn inpr mnob ocdi]||examined English literature until||February 24 2022 on Web of Science[ftcn inpr mnob ocdi]	We[ftcn inpr mnob ocdi]||examined English literature until||February 24 2022 on Web with seroprevalence[inpr tmco resa idcn orgf]	We[ftcn inpr mnob ocdi]||examined English literature until||February 24 2022 on Web of Science with seroprevalence[inpr tmco resa idcn orgf]	
We[fndg qlco]||identified||six studies[lbpr qnco]	

results[acty]||build||longitudinal model[spco inpr clna cnce]	results[acty]||be used||build[cnce]	results[acty]||be used||to build[cnce]	results[acty]||build||model[spco inpr clna cnce]	

testing data[euka medd inpr idcn ftcn]||include||significant number of false positive results[qlco fndg idcn qnco]	testing data[euka medd inpr idcn ftcn]||include||significant number of false results[qlco fndg idcn qnco]	testing data[euka medd inpr idcn ftcn]||include||number of false positive results[qlco fndg idcn qnco]	testing data[euka medd inpr idcn ftcn]||include||number of false results[qlco fndg idcn qnco]	
convenience sampling[euka medd hcro resa idcn ftcn]||obtained||data reporting[hlca]	convenience sampling[euka medd hcro resa idcn ftcn]||obtained||data from health department[euka medd hcro resa idcn ftcn]	convenience sampling[euka medd hcro resa idcn ftcn]||obtained||data from health department reporting[euka medd hcro resa idcn ftcn]	convenience sampling[euka medd hcro resa idcn ftcn]||obtained||data reporting seriously[hlca]	
based epidemiology[resa]||may||may method of estimating[lbpr inpr qlco ftcn qnco]	epidemiology[resa]||be effective||estimating[lbpr inpr qlco ftcn qnco]	based epidemiology[resa]||may||In contrast may method of estimating[lbpr inpr qlco ftcn qnco]	based epidemiology[resa]||may||may cost effective method of estimating[lbpr inpr qlco ftcn qnco]	

Abstract 22
Atrial fibrillation AF[dsyn fndg gngm lbtr]||is major cause with||high prevalence among elderly[ftcn popg inpr qnco]	Atrial fibrillation AF[dsyn fndg gngm lbtr]||is major cause with||prevalence among elderly[ftcn popg inpr qnco]	fibrillation AF[dsyn fndg gngm lbtr]||is major cause with||high prevalence among elderly[ftcn popg inpr qnco]	Atrial fibrillation AF[dsyn fndg gngm lbtr]||is cause with||high prevalence among elderly[ftcn popg inpr qnco]	
Surgery[ftcn bmod topp]||is known||AFhowever[mnob bacs fndg spco qlco idcn orch cnce]	
purpose[resa]||was identify||Single Nucleotide Polymorphisms[nusq]	purpose[resa]||was identify||Nucleotide Polymorphisms[nusq]	purpose[resa]||was identify||Single Nucleotide Polymorphisms associated[nusq]	purpose[resa]||was identify||Single Nucleotide Polymorphisms associated with AF[nusq]	
UK Biobank[qlco]||conduct||Genome Wide Association Study GWAS[mbrt]	Association Study GWAS[mbrt]||identify||variants[qlco]	UK Biobank[qlco]||conduct||Association Study GWAS[mbrt]	Association Study GWAS[mbrt]||identify||variants associated with AF[gngm lbtr qlco]	
initial discovery GWAS[acty mbrt qlco tmco idcn ftcn]||was performed in||patients[ftcn podg]	discovery GWAS[acty mbrt qlco tmco idcn ftcn]||was performed in||patients[ftcn podg]	initial discovery GWAS[acty mbrt qlco tmco idcn ftcn]||was||performed[ftcn podg]	discovery GWAS[acty mbrt qlco tmco idcn ftcn]||was||performed[ftcn podg]	
cases[ftcn qnco]||were defined In||unique non-surgical cohort[ftcn popg qnco qlco]	cases[ftcn qnco]||were defined within||30 days after surgery[ftcn bmod fndg topp]	cases[ftcn qnco]||were defined as||newly diagnosed AF[lbtr diap inpr gngm idcn cnce]	cases[ftcn qnco]||were defined In||non-surgical cohort[ftcn popg qnco qlco]	
threshold[idcn qnco qlco]||was||set[ftcn cnce menp qnco]	
144,196 surgical patients[nusq podg]||were left After||quality control[ftcn inpr]	144,196 surgical patients[nusq podg]||were left for||analysis[ftcn spco resa lbpr]	surgical patients[nusq podg]||were left After||quality control[ftcn inpr]	surgical patients[nusq podg]||were left for||analysis[ftcn spco resa lbpr]	
Two variants[qlco qnco]||reached||statistical significance[qnco]	variants[qlco qnco]||reached||statistical significance[qnco]	Two variants[qlco qnco]||reached||significance[qnco]	variants[qlco qnco]||reached||significance[qnco]	
Two variants[qlco qnco]||were replicated in||unique non-surgical cohort[ftcn popg qnco qlco]	Two variants[qlco qnco]||were replicated in||non-surgical cohort[ftcn popg qnco qlco]	variants[qlco qnco]||were replicated in||unique non-surgical cohort[ftcn popg qnco qlco]	variants[qlco qnco]||were replicated in||non-surgical cohort[ftcn popg qnco qlco]	
other loci[spco]||were associated in||unique non-surgical cohort[ftcn popg qnco qlco]	other loci[spco]||were associated in||non-surgical cohort[ftcn popg qnco qlco]	other loci[spco]||were significantly associated in||unique non-surgical cohort[ftcn popg qnco qlco]	Several loci[qnco]||were associated in||unique non-surgical cohort[ftcn popg qnco qlco]	
we[fndg qlco]||identified||2 variants[fndg lbtr inpr qlco qnco]	we[fndg qlco]||identified In||GWAS analysis of large national biobank[fndg lbpr spco mbrt popg resa gngm ftcn qnco]	we[fndg qlco]||identified In||GWAS analysis of national biobank[fndg lbpr spco mbrt popg resa gngm ftcn qnco]	we[fndg qlco]||identified In||GWAS analysis of large biobank[fndg lbpr spco mbrt popg resa gngm ftcn qnco]	
Two variants[qlco qnco]||were replicated in||unique non-surgical cohort[ftcn popg qnco qlco]	variants[qlco qnco]||were replicated in||unique non-surgical cohort[ftcn popg qnco qlco]	Two variants[qlco qnco]||were replicated in||non-surgical cohort[ftcn popg qnco qlco]	Two variants[qlco qnco]||were subsequently replicated in||non-surgical cohort[ftcn popg qnco qlco]	
findings[ftcn inpr clna]||bring||new insight in genetics of postoperative AF[bmod lbtr lang tmco qlco gngm ftcn menp]	findings[ftcn inpr clna]||bring||insight in genetics of postoperative AF[bmod lbtr lang tmco qlco gngm ftcn menp]	findings[ftcn inpr clna]||bring||new insight in genetics of AF[bmod lbtr lang tmco qlco gngm ftcn menp]	findings[ftcn inpr clna]||bring||insight in genetics of AF[bmod lbtr lang tmco qlco gngm ftcn menp]	

Abstract 23
Solid organ transplant recipients[podg]||have attenuated responses to||SARS CoV 2 vaccines[phsu imft ortf virs]	organ transplant recipients[podg]||have attenuated responses to||SARS CoV 2 vaccines[phsu imft ortf virs]	Solid organ transplant recipients[podg]||have attenuated to||SARS CoV 2 vaccines[phsu imft ortf virs]	Solid organ transplant recipients[podg]||have attenuated||immune responses[phsu imft ortf virs]	
3rd V3 doses[bpoc qnco]||is in||kidney transplant population[bpoc phsu bodm popg gngm topp imft aapp qnco]	we[clna inpr ortf hlca]||report on||immune responses[clna inpr ortf hlca]	we[clna inpr ortf hlca]||report on||responses to V3 doses of heterologous vaccines[elii qlco qnco]	we[clna inpr ortf hlca]||report on||responses to 3rd V3 doses of heterologous vaccines[elii qlco qnco]	
724 kidney transplant recipients[podg]||were screened following||3 primary doses of SARS CoV2 vaccine[fndg inpr qlco tmco dsyn topp virs qnco]	kidney transplant recipients[podg]||were screened following||3 primary doses of SARS CoV2 vaccine[fndg inpr qlco tmco dsyn topp virs qnco]	724 kidney transplant recipients[podg]||were screened following||3 doses of SARS CoV2 vaccine[fndg inpr qlco tmco dsyn topp virs qnco]	724 kidney transplant recipients[podg]||were prospectively screened following||3 primary doses of SARS CoV2 vaccine[fndg inpr qlco tmco dsyn topp virs qnco]	
322 patients[podg qnco]||were sampled with||69 assessment of SARS CoV 2 T cell responses[acty hlca cell orga virs]	322 patients[podg qnco]||were sampled for||anti-S[imft aapp]	322 patients[podg qnco]||were sampled post-V4 for||anti-S[imft aapp]	322 patients[podg qnco]||were sampled with||69 undergoing assessment of SARS CoV 2 T cell responses[acty hlca cell orga virs]	
vaccine doses[phsu imft aapp qnco]||were||received[qlco]	

Results586 724 80.9 patients[podg qnco]||were||remained at 31 21 51 days post-V3[mnob bpoc tmco gngm qnco]	Results586 724 patients[podg qnco]||were||remained at 31 21 51 days post-V3[mnob bpoc tmco gngm qnco]	Results586 724 80.9 patients[podg qnco]||were||remained at 31 21 51 days[mnob bpoc tmco gngm qnco]	Results586 724 patients[podg qnco]||were||remained at 31 21 51 days[mnob bpoc tmco gngm qnco]	
Results586 724 80.9 patients[podg qnco]||were||remained at 31 21 51 days post-V3[mnob bpoc tmco gngm qnco]	Results586 724 patients[podg qnco]||were||remained at 31 21 51 days post-V3[mnob bpoc tmco gngm qnco]	Results586 724 80.9 patients[podg qnco]||were||remained at 31 21 51 days[mnob bpoc tmco gngm qnco]	Results586 724 patients[podg qnco]||were||remained at 31 21 51 days[mnob bpoc tmco gngm qnco]	
Seropositive patients[mnob bpoc tmco qlco gngm podg]||post-V3 had||greater anti-S[imft aapp qnco]	Seropositive patients[mnob bpoc tmco qlco gngm podg]||had||greater anti-S[imft aapp qnco]	patients[imft aapp qnco]||post-V3 had||greater anti-S[imft aapp qnco]	Seropositive patients[mnob bpoc tmco qlco gngm podg]||post-V3 had||anti-S[imft aapp qnco]	
De novo seroconversion post-V4[mnob fndg elii tmco gngm idcn npop]||occurred in||15/60 25.0 patients[podg acty qnco]	

Anti-S post-V4[mnob elii tmco gngm imft aapp]||were||sequentially greater[mnob bpoc tmco gngm blor qnco]	Anti-S post-V4[mnob elii tmco gngm imft aapp]||were||greater[bpoc acty]	post-V4[mnob elii tmco gngm imft aapp]||were||sequentially greater[mnob bpoc tmco gngm blor qnco]	post-V4[mnob elii tmco gngm imft aapp]||were||greater[bpoc acty]	

Conclusion[idcn]||remain following||3 - doses of SARS CoV 2 vaccines[fndg virs qnco]	Conclusion[idcn]||remain||seronegative[lbtr]	Conclusion[idcn]||remain with||poor T cell responses[cell inpr grpa qlco orga]	Conclusion[idcn]||remain following||3 - doses[cell inpr grpa qlco orga]	

Abstract 24
Parkinsons disease PD[fndg dsyn inpr ftcn]||is||progressive neurodegenerative disorder[comd]	Parkinsons disease PD[fndg dsyn inpr ftcn]||is||disorder characterized by accumulation of abnormal isoforms of alpha synuclein[bacs fndg acty inpr gngm aapp qnco]	Parkinsons disease PD[fndg dsyn inpr ftcn]||is||progressive disorder characterized by accumulation of abnormal isoforms of alpha synuclein[bacs fndg acty inpr gngm aapp qnco]	Parkinsons disease PD[fndg dsyn inpr ftcn]||is||disorder characterized by accumulation of isoforms of alpha synuclein[bacs fndg acty inpr gngm aapp qnco]	
pathologic state alpha synuclein[bacs geoa inpr qlco gngm ftcn aapp]||causes||damage as alpha synuclein accumulates[bacs inpo gngm ftcn aapp]	pathologic state alpha synuclein[bacs geoa inpr qlco gngm ftcn aapp]||causes||neuronal damage as alpha synuclein accumulates[bacs inpo gngm ftcn aapp]	pathologic state alpha synuclein[bacs geoa inpr qlco gngm ftcn aapp]||causes||neuronal damage alpha synuclein accumulates[bacs inpo gngm ftcn aapp]	pathologic state alpha synuclein[bacs geoa inpr qlco gngm ftcn aapp]||causes||damage alpha synuclein accumulates[bacs inpo gngm ftcn aapp]	
alpha synuclein[bacs aapp gngm]||remains||controversial[socb]	
We[fndg]||have previously developed||Removed SIR computational model[acty inpr qlco resa cnce clna]	We[fndg]||have developed||Removed SIR computational model[acty inpr qlco resa cnce clna]	We[fndg]||have previously developed||SIR computational model[acty inpr qlco resa cnce clna]	We[fndg]||have developed||SIR computational model[acty inpr qlco resa cnce clna]	
We[lbpr lbtr inpr blor ftcn]||test||Removed SIR computational model[acty inpr qlco resa cnce clna]	We[lbpr lbtr inpr blor ftcn]||test||SIR computational model[acty inpr qlco resa cnce clna]	We[lbpr lbtr inpr blor ftcn]||test||Removed SIR model[acty inpr qlco resa cnce clna]	We[lbpr lbtr inpr blor ftcn]||Here test||Removed SIR computational model[acty inpr qlco resa cnce clna]	
brain deformation[ftcn bpoc]||progresses in||regions[spco geoa bpoc]	brain deformation[ftcn bpoc]||progresses in||subcortical regions[spco geoa bpoc]	
SIR model[cnce inpr clna]||using||structural connectivity[ftcn spco diap]	SIR model[cnce inpr clna]||using||connectivity[ftcn spco diap]	SIR model[cnce inpr clna]||using structural connectivity from||diffusion MRI[ftcn spco diap]	SIR model[cnce inpr clna]||using from||diffusion MRI[ftcn spco diap]	
geometry[ocdi]||contribute to||model fit[fndg acty inpr sosy cnce clna]	connectome topology[bmod anst]||contribute to||model fit[fndg acty inpr sosy cnce clna]	geometry[ocdi]||significantly contribute to||model fit[fndg acty inpr sosy cnce clna]	connectome topology[bmod anst]||significantly contribute to||model fit[fndg acty inpr sosy cnce clna]	

Removed SIR computational model[acty inpr qlco resa cnce clna]||investigate||multifactorial neurodegenerative diseases[dsyn fndg tmco]	SIR computational model[acty inpr qlco resa cnce clna]||investigate||multifactorial neurodegenerative diseases[dsyn fndg tmco]	Removed SIR computational model[acty inpr qlco resa cnce clna]||investigate||neurodegenerative diseases[dsyn fndg tmco]	Removed SIR computational model[acty inpr qlco resa cnce clna]||investigate||multifactorial diseases[dsyn fndg tmco]	

Abstract 25
Recommendations[acty menp]||consider||consistency of application[inpr qlco topp ftcn qnco]	Recommendations[acty menp]||consider||consistency of application resulting[inpr qlco topp ftcn qnco]	Recommendations[acty menp]||consider||consistency resulting[inpr qlco topp ftcn qnco]	Recommendations[acty menp]||consider||consistency resulting in treatment decisions[fndg hlca spco resa gngm topp ftcn cnce menp]	
biases[idcn]||underlying||patient mortality risk[idcn cnce podg qnco]	biases[idcn]||underlying||mortality risk[idcn cnce podg qnco]	we[idcn]||examine||four datasets[inpr qnco]	we[idcn]||characterize||impact of choices[inbe gngm qlco]	
treatment decisions[hlca resa topp ftcn cnce menp]||produce||step function changes in risk near clinically important round number cutoffs[fndg spco inpr qlco idcn topp ftcn cnce qnco]	step function changes[mnob phsf inpr orga ftcn cnce qnco]||is in||risk near clinically important round number cutoffs[fndg spco inpr qlco idcn topp ftcn cnce qnco]	we[spco]||document||two types of suboptimalities[fndg clas qlco tmco qnco]	treatment decisions[hlca resa topp ftcn cnce menp]||produce||step function changes in risk near important round number cutoffs[fndg spco inpr qlco idcn topp ftcn cnce qnco]	
outcomes[ftcn]||improved over||decades of refinement of clinical practice[mnob fndg inpr qlco menp qnco]	outcomes[ftcn]||improved over||decades of refinement of practice[mnob fndg inpr qlco menp qnco]	outcomes[ftcn]||improved over||decades of refinement[mnob fndg inpr qlco menp qnco]	outcomes[ftcn]||improved over||decades[idcn]	
we[acty]||provide||recommendations for clinical practice[mnob inpr qlco idcn menp]	we provide[acty]||can transform||challenges of statistical confounding[hlca ocdi]	we[acty]||provide||recommendations for practice[mnob inpr qlco idcn menp]	we provide[acty]||can transform||challenges statistical confounding[hlca ocdi]	

Abstract 26
Photoplethysmography PPG[diap gngm]||is||cost method measure[ftcn qnco]	Photoplethysmography PPG[diap gngm]||is||cost method to measure[ftcn qnco]	Photoplethysmography PPG[diap gngm]||is||low cost method measure[ftcn qnco]	Photoplethysmography PPG[diap gngm]||is||low cost method to measure[ftcn qnco]	
method[ftcn inpr lbpr]||is widely used in||various wearable devices[mnob phsu fndg imft]	method[ftcn inpr lbpr]||is used in||various wearable devices[mnob phsu fndg imft]	method[ftcn inpr lbpr]||is widely used in||wearable devices[mnob phsu fndg imft]	method[ftcn inpr lbpr]||is widely used in||various devices[mnob phsu fndg imft]	
Samsung smartwatches[fndg spco inpr gngm topp idcn ftcn]||are||PPG based open source wristbands[fndg spco inpr gngm topp idcn ftcn]	Samsung smartwatches[fndg spco inpr gngm topp idcn ftcn]||are||based open source wristbands[fndg spco inpr gngm topp idcn ftcn]	Samsung smartwatches[fndg spco inpr gngm topp idcn ftcn]||are||PPG based source wristbands[fndg spco inpr gngm topp idcn ftcn]	Samsung smartwatches[fndg spco inpr gngm topp idcn ftcn]||are||PPG based open source wristbands used[fndg spco inpr gngm topp idcn ftcn]	
PPG[gngm]||is highly susceptible to||motion artifacts[mnob lbtr orga qlco ftcn npop hcpp]	PPG[gngm]||However is highly susceptible to||motion artifacts[mnob lbtr orga qlco ftcn npop hcpp]	PPG[gngm]||is susceptible to||motion artifacts[mnob lbtr orga qlco ftcn npop hcpp]	PPG[gngm]||However is susceptible to||motion artifacts[mnob lbtr orga qlco ftcn npop hcpp]	
validation study[resa inpr]||investigate||accuracy of PPG based wearable devices[mnob qlco gngm idcn ftcn]	validation study[resa inpr]||investigate||accuracy of based wearable devices[mnob qlco gngm idcn ftcn]	validation study[resa inpr]||is required||investigate[ftcn]	validation study[resa inpr]||investigate||accuracy of wearable devices[mnob qlco gngm idcn ftcn]	
PPG[gngm]||evaluate||accuracy of PPG signals[phpr ftcn gngm qlco]	PPG[gngm]||evaluate||accuracy of PPG signals collected[phpr ftcn gngm qlco]	PPG[gngm]||evaluate||accuracy of PPG signals collected by Samsung Gear Sport smartwatch[mnob ftcn idcn]	PPG[gngm]||evaluate||accuracy of PPG signals collected by Samsung Gear Sport smartwatch in terms[mnob ftcn idcn]	
PPG[gngm]||conducted||24 hours monitoring[hlca]	PPG[gngm]||conducted||24 hours monitoring using[hlca]	
they[qlco fndg tmco]||engaged in||routines[ftcn]	they[qlco fndg tmco]||engaged in||daily routines[qlco fndg tmco]	
PPG[gngm]||evaluated||HR parameters[orgf fndg geoa lang]	PPG[gngm]||evaluated during||sleep[hlca]	PPG[gngm]||evaluated HR parameters during||sleep[hlca]	
HR parameters[fndg geoa lang]||extracted from||smartwatch[fndg topp]	
PPG[gngm]||employed||Pearson correlation coefficient[qnco]	PPG[gngm]||employed Pearson correlation coefficient For||comparison[acty]	PPG[gngm]||employed For||comparison[acty]	
PPG[gngm]||found at_time||HR[diap]	PPG[gngm]||found correlation at_time||HR[diap]	
mean biases[idcn qnco]||were||while moderate during sleep[fndg orgf inpr qlco]	mean biases[idcn qnco]||were||low[fndg inpr qnco qlco]	mean biases[idcn qnco]||were moderate during||sleep[fndg orgf inpr qlco]	mean biases[idcn qnco]||were low||moderate[fndg orgf inpr qlco]	
regression analysis[inpr]||showed||low error variances of HR[fndg inpr qlco ftcn qnco]	regression analysis[inpr]||showed||error variances of HR[fndg inpr qlco ftcn qnco]	regression analysis[inpr]||showed||low error variances[fndg inpr qlco ftcn qnco]	regression analysis[inpr]||showed||error variances[fndg inpr qlco ftcn qnco]	
HR parameters[fndg geoa lang]||indicated||significantly low positive correlations[qlco fndg comd qnco]	HR parameters[fndg geoa lang]||indicated||significantly low correlations[qlco fndg comd qnco]	HR parameters[fndg geoa lang]||indicated||low positive correlations[qlco fndg comd qnco]	HR parameters[fndg geoa lang]||indicated||positive correlations[qlco fndg comd qnco]	
HR parameters[fndg geoa lang]||had||moderate mean biases[fndg inpr qlco idcn qnco]	HR parameters[fndg geoa lang]||had||moderate biases[fndg inpr qlco idcn qnco]	HR parameters[fndg geoa lang]||had||mean biases[fndg inpr qlco idcn qnco]	RMSSD[fndg geoa lang]||showed||low mean biases[fndg inpr qlco idcn qnco]	
HR parameters[fndg geoa lang]||indicated||high error variances[fndg inpr qlco idcn ftcn qnco]	HR parameters[fndg geoa lang]||indicated||error variances[fndg inpr qlco idcn ftcn qnco]	AVNN[fndg geoa lang]||had error variance In||addition[ftcn]	AVNN[fndg geoa lang]||had error variance||HR parameters indicated[fndg geoa lang]	
Samsung smartwatch[fndg enzy elii tmco gngm aapp orgf]||provides||acceptable HR[qlco]	Samsung smartwatch[fndg enzy elii tmco gngm aapp orgf]||provides||HR[qlco]	Samsung smartwatch[fndg enzy elii tmco gngm aapp orgf]||provides during||sleep time[fndg enzy elii tmco gngm aapp orgf]	Samsung smartwatch[fndg enzy elii tmco gngm aapp orgf]||provides HR during||sleep time[fndg enzy elii tmco gngm aapp orgf]	
HR[fndg geoa lang]||show||satisfactory accuracy[ftcn inpr qlco]	HR parameters[fndg geoa lang]||have||high errors[fndg inpr idcn qlco]	AVNN[fndg geoa lang]||show||satisfactory accuracy[ftcn inpr qlco]	HR parameters[fndg geoa lang]||have||errors[fndg inpr idcn qlco]	

Abstract 27
work[ocac]||presents||methodology[inpr idcn]	superspreading events[clas evnt idcn ftcn qnco]||occurring on||key calendar dates[ftcn food acty tmco]	superspreading events[clas evnt idcn ftcn qnco]||occurring on||calendar dates[ftcn food acty tmco]	work[ocac]||presents to||recreate[fndg idcn]	
COVID 19 pandemic dynamics[npop dsyn]||is in||Mexico[geoa]	method[ftcn inpr lbpr]||is illustrated by||COVID 19 pandemic dynamics[npop dsyn]	method[ftcn inpr lbpr]||is illustrated by||COVID 19 pandemic dynamics up[npop dsyn]	method[ftcn inpr lbpr]||is illustrated by||COVID 19 pandemic dynamics in Mexico[npop dsyn]	
dynamic[ftcn dsyn]||is||determined by[fndg inpr clna qlco]	dynamic[ftcn dsyn]||is||determined[fndg inpr clna qlco]	
historical changes[fndg acty inpr qlco popg idcn ftcn qnco]||are||estimated[qnco]	historical changes[fndg acty inpr qlco popg idcn ftcn qnco]||are||First estimated[qnco]	historical changes[fndg acty inpr qlco popg idcn ftcn qnco]||is in||effective contact rate on predetermined dates[food tmco]	changes[fndg acty inpr qlco popg idcn ftcn qnco]||are||estimated[qnco]	
information[idcn]||is||Then used[tmco]	information[idcn]||is used||will similar[qlco]	to forecast[ftcn fndg inpr]||be||similar[qlco]	trends[food tmco]||observed in||past[ftcn gngm tmco]	
other conditions[inpr qlco dsyn cnce clna]||are assumed||remain in time scale of projections[acty spco medd inpr tmco qlco menp qnco]	other conditions[inpr qlco dsyn cnce clna]||are assumed||to remain in time scale of projections[acty spco medd inpr tmco qlco menp qnco]	other conditions[inpr qlco dsyn cnce clna]||are||assumed[inpr]	other conditions[inpr qlco dsyn cnce clna]||are assumed||to remain in time scale[acty spco medd inpr tmco qlco menp qnco]	
methodology[inpr idcn]||avoids||necessity of fixing values of dynamic parameters[ftcn cnce lbpr]	methodology[inpr idcn]||avoids||necessity of values of dynamic parameters[ftcn cnce lbpr]	methodology[inpr idcn]||avoids||necessity of fixing values of parameters[ftcn cnce lbpr]	methodology[inpr idcn]||necessity of||fixing values of dynamic parameters[ftcn cnce lbpr]	
Results[ftcn fndg idcn]||show||that considering dates[idcn]	Results[ftcn fndg idcn]||show||that considering key dates[idcn]	Results[ftcn fndg idcn]||show||that[idcn]	

Abstract 28
we[spco medd]||calculated||vaccine volume[lbpr phsu inpr qlco imft aapp qnco]	dead space[spco orgf qnco]||is in||syringe[medd qnco]	we[spco medd]||calculated In||current study[mnob resa npop tmco]	we[spco medd]||calculated in||syringe[medd qnco]	
hypothetical situation[spco medd qnco qlco]||uses as||ChAdox1 n CoV vial[medd qnco]	hypothetical situation[spco medd qnco qlco]||uses vial as||ChAdox1 n CoV vial[medd qnco]	hypothetical situation[spco medd qnco qlco]||uses||vial[spco medd qnco qlco]	hypothetical situation[spco medd qnco qlco]||uses with||similar size[spco medd qnco qlco]	
we[fndg]||used||fill[acty]	we[fndg]||used||to fill as five vials of ChAdox1 n CoV[lbpr phsu medd inpr qlco imft aapp qnco]	we[fndg]||used||distilled water[inch bacs phsu popg gngm aapp qnco]	we[fndg]||used||fill as five vials of ChAdox1 n CoV[lbpr phsu medd inpr qlco imft aapp qnco]	

1 mL syringe needle[bacs medd popg gngm aapp qnco]||administer||ChAdox1 n CoV vaccine[phsu imft aapp qnco]	1 mL syringe needle[bacs medd popg gngm aapp qnco]||administer into||12 doses using[ftcn]	1 mL syringe needle[bacs medd popg gngm aapp qnco]||administer ChAdox1 n CoV vaccine into||12 doses using[ftcn]	1 mL syringe needle[bacs medd popg gngm aapp qnco]||administer into||12 doses[spco medd]	
vaccine volume[lbpr phsu inpr qlco imft aapp qnco]||save||budget of low dead space syringe LDS[fndg spco inpr medd qlco popg orgf qnco]	vaccine volume[lbpr phsu inpr qlco imft aapp qnco]||save||budget of dead space syringe LDS[fndg spco inpr medd qlco popg orgf qnco]	vaccine volume[lbpr phsu inpr qlco imft aapp qnco]||save||budget of low space syringe LDS[fndg spco inpr medd qlco popg orgf qnco]	vaccine volume[lbpr phsu inpr qlco imft aapp qnco]||save||budget of space syringe LDS[fndg spco inpr medd qlco popg orgf qnco]	

Abstract 29
gap[spco idcn]||has in||has focus of researches for decades[resa qnco]	gap[spco idcn]||has in||has focus[ftcn spco]	gap[spco idcn]||has in||has focus of researches[ftcn spco]	
new knowledge[inpr lang qlco]||must work||successful implementation means[cnce socb acty qlco]	new knowledge[inpr lang qlco]||must work in||particular environments[spco]	new knowledge[inpr lang qlco]||must work||Although successful implementation means[cnce socb acty qlco]	entire process[hlca bpoc qnco ftcn phpr]||be executed by||individual institutes[orgt popg acty]	
intermediate step[mnob fndg lbtr spco inpr ftcn cnce qnco]||help||ensure[food]	intermediate step[mnob fndg lbtr spco inpr ftcn cnce qnco]||help||to ensure[food]	step[inpr qlco]||help||ensure[food]	step[inpr qlco]||help||to ensure[food]	
development[ocac]||was based||on we infinitE[inpr idcn ftcn cnce clna]	development[ocac]||was based||we infinitE[inpr idcn ftcn cnce clna]	development[ocac]||was||based[ftcn]	we[ftcn]||infinitE||model[inpr idcn ftcn cnce clna]	
general good practice methodology[bmod inpr idcn qlco]||organised||editing of development of general good practice methodology[mnob bmod fndg lbpr spco inpr qlco idcn ftcn orgf menp]	general good practice methodology[bmod inpr idcn qlco]||organised||editing of development of general practice methodology[mnob bmod fndg lbpr spco inpr qlco idcn ftcn orgf menp]	general good practice methodology[bmod inpr idcn qlco]||organised||editing of development of good practice methodology[mnob bmod fndg lbpr spco inpr qlco idcn ftcn orgf menp]	general good practice methodology[bmod inpr idcn qlco]||organised||editing[ocac]	
general good practice methodology[bmod inpr idcn qlco]||was finalized After||pilot testing[ftcn prog gngm inpr]	general practice methodology[bmod inpr idcn qlco]||was finalized After||pilot testing[ftcn prog gngm inpr]	general good practice methodology[bmod inpr idcn qlco]||was finalized to||other topics[ftcn inpr]	good practice methodology[bmod inpr idcn qlco]||was finalized After||pilot testing[ftcn prog gngm inpr]	
general good practice methodology[bmod inpr idcn qlco]||presented in||paper[mnob idcn]	general good practice methodology[bmod inpr idcn qlco]||presented in||detail[ftcn idcn qlco]	general practice methodology[bmod inpr idcn qlco]||presented in||paper[mnob idcn]	general practice methodology[bmod inpr idcn qlco]||presented in||detail[ftcn idcn qlco]	
general good practice methodology[bmod inpr idcn qlco]||has also proved Beside||pilot topic of institutional process of resuscitation[mnob bpoc hlca inpr hcro gngm topp idcn ftcn prog phpr]	general good practice methodology[bmod inpr idcn qlco]||has proved Beside||pilot topic of institutional process of resuscitation[mnob bpoc hlca inpr hcro gngm topp idcn ftcn prog phpr]	general practice methodology[bmod inpr idcn qlco]||has also proved Beside||pilot topic of institutional process of resuscitation[mnob bpoc hlca inpr hcro gngm topp idcn ftcn prog phpr]	good practice methodology[bmod inpr idcn qlco]||has also proved Beside||pilot topic of institutional process of resuscitation[mnob bpoc hlca inpr hcro gngm topp idcn ftcn prog phpr]	
general good practices[bmod qlco]||demonstrate||evidence in operation[acty topp idcn]	general practices[bmod qlco]||demonstrate||evidence in operation[acty topp idcn]	good practices[bmod qlco]||demonstrate||evidence in operation[acty topp idcn]	general good practices[bmod qlco]||demonstrate evidence Compared||guidelines[inpr acty]	

healthcare institutions[hcro hlca mnob idcn]||build on||these[mnob spco tmco ftcn cnce qnco]	healthcare institutions[hcro hlca mnob idcn]||build on||these in healthcare institutions[mnob hlca hcro idcn cnce]	
Further studies[spco lbpr]||could explore||applicability of general good practice methodology[bmod inpr idcn qlco]	Further studies[spco lbpr]||could explore||applicability of general practice methodology[bmod inpr idcn qlco]	Further studies[spco lbpr]||could explore||applicability of general good practice methodology at levels[bmod inpr idcn qlco]	Further studies[spco lbpr]||could explore||applicability of good practice methodology[bmod inpr idcn qlco]	

Abstract 30
treatment[fndg euka hlca dsyn resa topp ftcn cnce]||increase||probability of survival of patient[ftcn podg acty qnco]	treatment[fndg euka hlca dsyn resa topp ftcn cnce]||increase||probability of survival[ftcn podg acty qnco]	early recognition[menp tmco]||is||essential[qlco]	recognition[menp tmco]||is||essential[qlco]	
sepsis[fndg dsyn euka]||is||syndrome influenced by site of infection[cnce dsyn]	sepsis[fndg dsyn euka]||is||complex syndrome influenced by site of infection[cnce dsyn]	sepsis[fndg dsyn euka]||is||complex syndrome[dsyn orga qlco]	sepsis[fndg dsyn euka]||is||syndrome influenced by site[cnce dsyn]	
early diagnosis[diap]||is challenge||must evaluated[hlca]	early diagnosis[diap]||So is challenge||must evaluated[hlca]	diagnosis[diap]||is challenge||must evaluated[hlca]	diagnosis[diap]||So is challenge||must evaluated[hlca]	
list involved[inpr qlco]||is provided In||paper[mnob idcn]	list involved[inpr qlco]||is||provided[acty]	list[inpr qlco]||is provided In||paper[mnob idcn]	list[inpr qlco]||is||provided[acty]	
emergency room[hcro mnob]||model based||machine learning[inpr]	emergency room[hcro mnob]||is||proposed[qlco]	
gradient[mnob]||was||trained[mnob]	gradient[mnob]||was trained with||cross validation[resa hlca]	
model[cnce inpr clna]||achieve up to||97 mean per class accuracy[clas inpr qlco ftcn cnce]	

Abstract 31

529 variant first[qlco qnco]||emerged with||extensive escape from neutralizing immunity[phsf inpr qlco ftcn menp]	529 variant first[qlco qnco]||emerged with||extensive escape from neutralizing immunity elicited[phsf inpr qlco ftcn menp]	previous infection[dsyn patf tmco qlco]||is with||other variants[qlco]	529 variant first[qlco qnco]||emerged with||escape from neutralizing immunity[phsf inpr qlco ftcn menp]	
Two new sub-lineages[spco lang qlco cnce qnco]||are emerging with||changes relative to BA .1[orch phsu idcn]	Two new sub-lineages[spco lang qlco cnce qnco]||are now emerging with||changes relative to BA .1[orch phsu idcn]	Two new sub-lineages[spco lang qlco cnce qnco]||are emerging with||changes[ftcn qnco]	Two new sub-lineages[spco lang qlco cnce qnco]||are now emerging with||changes[ftcn qnco]	
BA .1 infection[phsu patf qlco dsyn orch]||is in||participants[popg]	We[ftcn idcn]||isolated||BA .4 .5 viruses[ftcn popg virs]	We[ftcn idcn]||isolated||live BA .4 .5 viruses[ftcn popg virs]	We[ftcn idcn]||tested||BA .4 viruses[ftcn popg virs]	

FRNT50[inpr]||declined In||vaccinated BA .1 breakthroughs[orch phsu fndg qlco]	FRNT50[inpr]||declined for||3.2-fold for BA .5 2.6-fold[orch spco phsu]	FRNT50[inpr]||declined In||BA .1 breakthroughs[orch phsu fndg qlco]	FRNT50[inpr]||declined for||3.2-fold 2.6-fold[orch spco phsu]	


BA .4[popg]||is in||particularly unvaccinated group[ftcn cnce popg idcn]	

Abstract 32
infectious particles[chvs dsyn patf]||be shared through||respiration[biof phsf celf ftcn socb]	particles[chvs dsyn patf]||be shared through||respiration[biof phsf celf ftcn socb]	infectious particles[chvs dsyn patf]||be||shared[biof phsf celf ftcn socb]	whether can passed[fndg grpa dsyn ftcn qnco]||has||Despite obvious knowledge has postulated[inpr]	
unique opportunity[qlco]||fully examine||provocative idea[qlco phpr]	unique opportunity[qlco]||examine||provocative idea[qlco phpr]	opportunity[qlco]||fully examine||provocative idea[qlco phpr]	opportunity[qlco]||examine||provocative idea[qlco phpr]	
herd immunity[phsf]||may||may manifested[ftcn qlco]	

Abstract 33
Omicron variant outbreak[clas inpr qlco tmco phpr]||is in||Shanghai[menp]	
Omicron variant outbreak[clas inpr qlco tmco phpr]||is in||Shanghai[menp]	
Clinical data vaccination status[dsyn fndg]||were||collected[ftcn idcn]	data vaccination status[dsyn fndg]||were||collected[ftcn idcn]	
Relative risks RR[fndg qnco]||assess||effect of vaccination[fndg topp qlco]	Relative risks RR[fndg qnco]||assess||effect on symptomatic infection[ftcn dsyn patf]	Relative risks RR[fndg qnco]||were calculated||assess[acty]	Relative risks RR[fndg qnco]||assess||effect of vaccination on infection[fndg topp qlco]	



Two dose COVID 19 vaccination[clna dsyn topp qnco]||reduced||risks of symptomatic infection[ftcn fndg]	dose COVID 19 vaccination[clna dsyn topp qnco]||reduced||risks of symptomatic infection[ftcn fndg]	Two dose COVID 19 vaccination[clna dsyn topp qnco]||reduced by||95 CI[lbpr qnco]	dose COVID 19 vaccination[clna dsyn topp qnco]||reduced by||95 CI[lbpr qnco]	
104 40.2[qnco]||had cough at_time||duration7 0.8 days[fndg sosy tmco qnco]	104 40.2[qnco]||had at_time||duration7 0.8 days[fndg sosy tmco qnco]	16.4[qnco]||had||transient leukopenia307 86[popg tmco]	epidemiological exposure[bmod phsu famg qlco inpo orch qnco]||is in||household 69.1[bmod phsu famg qlco inpo orch qnco]	
wide dissemination[spco inpr qlco]||is in||community[grup]	
Asymptomatic infection[dsyn]||is common among||Omicron infected children[fndg inpr famg ftcn aggp qnco]	Asymptomatic infection[dsyn]||is common among||infected children[fndg inpr famg ftcn aggp qnco]	Asymptomatic infection[dsyn]||is common among||children[fndg inpr famg ftcn aggp qnco]	infection[dsyn]||is common among||Omicron infected children[fndg inpr famg ftcn aggp qnco]	
COVID 19 vaccination[dsyn topp]||can offer||protection against symptomatic infection[ftcn topp]	COVID vaccination[dsyn topp]||can offer||protection against symptomatic infection[ftcn topp]	COVID 19 vaccination[dsyn topp]||can offer||protection against infection[ftcn topp]	COVID vaccination[dsyn topp]||can offer||protection against infection[ftcn topp]	

Abstract 34
CCP[phsu dsyn bdsu idcn]||was early||COVID[phsu dsyn bdsu idcn]	
Results[fndg sbst inpr qlco resa idcn ftcn cnce]||demonstrate||clear therapeutic role[qlco fndg inpr]	Results[fndg sbst inpr qlco resa idcn ftcn cnce]||demonstrate||role for very low antibody content CCP for severe SARS CoV 2 infection[fndg phsu inpr patf qlco dsyn celc cnce imft aapp virs menp]	Results[fndg sbst inpr qlco resa idcn ftcn cnce]||demonstrate||role for low antibody content CCP for severe SARS CoV 2 infection[fndg phsu inpr patf qlco dsyn celc cnce imft aapp virs menp]	Results[fndg sbst inpr qlco resa idcn ftcn cnce]||demonstrate||therapeutic role for low antibody content CCP for severe SARS CoV 2 infection[fndg phsu inpr patf qlco dsyn celc cnce imft aapp virs menp]	
Underlying[qlco]||is broad heterogeneity in||concentrations of neutralizing antibodies[phsu qlco orga imft aapp menp]	Underlying[qlco]||is heterogeneity in||concentrations of neutralizing antibodies[phsu qlco orga imft aapp menp]	broad heterogeneity[qlco]||is in||concentrations of neutralizing antibodies[phsu qlco orga imft aapp menp]	Underlying[qlco]||is broad heterogeneity in||concentrations of antibodies[phsu qlco orga imft aapp menp]	
present study[mnob idcn fndg resa]||evaluate||n Ab titer threshold[qlco imft aapp qnco]	present study[mnob idcn fndg resa]||was designed||evaluate[hlca]	present study[mnob idcn fndg resa]||evaluate n Ab titer threshold for||very low antibody content CCP[fndg phsu qlco celc cnce imft aapp menp]	present study[mnob idcn fndg resa]||evaluate for||very low antibody content CCP[fndg phsu qlco celc cnce imft aapp menp]	
n defined CCP[fndg inpr cnce imft aapp qnco]||conducted||double blind phase 2 study evaluate[resa tmco]	n defined CCP[fndg inpr cnce imft aapp qnco]||conducted||double blind phase 2 study to evaluate[resa tmco]	n defined CCP[fndg inpr cnce imft aapp qnco]||conducted||blind phase 2 study evaluate[resa tmco]	n defined CCP[fndg inpr cnce imft aapp qnco]||conducted||blind phase 2 study to evaluate[resa tmco]	
n defined CCP[fndg inpr cnce imft aapp qnco]||conducted||double blind phase 2 study evaluate[resa tmco]	n defined CCP[fndg inpr cnce imft aapp qnco]||conducted||double blind phase 2 study to evaluate[resa tmco]	n defined CCP[fndg inpr cnce imft aapp qnco]||conducted||blind phase 2 study evaluate[resa tmco]	n defined CCP[fndg inpr cnce imft aapp qnco]||conducted||blind phase 2 study to evaluate[resa tmco]	
low antibody content CCP[fndg lbpr lbtr cnce imft aapp menp]||is with||n Ab titers[fndg]	
Adverse events[inpr patf]||were contrasted by||very low antibody content CCP titer[fndg lbpr lbtr cnce imft aapp menp]	Adverse events[inpr patf]||were contrasted by||low antibody content CCP titer[fndg lbpr lbtr cnce imft aapp menp]	Adverse events[inpr patf]||were contrasted by||antibody content CCP titer[fndg lbpr lbtr cnce imft aapp menp]	events[inpr patf]||were contrasted by||very low antibody content CCP titer[fndg lbpr lbtr cnce imft aapp menp]	
primary clinical outcome[mnob tmco qlco topp ftcn]||was time with||mortality evaluated as secondary outcomes[ocac neop qnco qlco]	primary clinical outcome[mnob tmco qlco topp ftcn]||was time to||hospital discharge[hlca tmco]	primary clinical outcome[mnob tmco qlco topp ftcn]||was time with||mortality[qnco]	primary clinical outcome[mnob tmco qlco topp ftcn]||was time with||mortality evaluated as outcomes[ocac neop qnco qlco]	
316 participants[popg]||were screened||55 received CCP[fndg inpr qlco imft aapp]	participants[popg]||were screened||55 received CCP[fndg inpr qlco imft aapp]	316 participants[popg]||were screened||55 received CCP respectively[fndg inpr qlco imft aapp]	316 participants[popg]||were||screened[mnob diap lbpr]	
Participants[popg]||were median of||61 years of age IQR 52 67[spco tmco qnco]	Participants[popg]||were median of||61 years[popg qnco]	Participants[popg]||were||median[popg qnco]	


time[inpr qnco qlco]||was shorter among||participants accounting for death[ocac fndg orgf inpr]	time[inpr qnco qlco]||was shorter among||participants accounting as competing event hazard ratio 94 95[lbpr evnt qnco]	time[inpr qnco qlco]||was shorter among||participants accounting as event hazard ratio 94 95[lbpr evnt qnco]	time[inpr qnco qlco]||was shorter among||participants receiving accounting as competing event hazard ratio 94 95[lbpr evnt qnco]	
participants[popg]||receiving||that[popg]	low antibody content CCP[fndg lbpr lbtr cnce imft aapp menp]||is with||lower n Ab titer CCP[fndg imft aapp qnco]	low antibody content CCP[fndg lbpr lbtr cnce imft aapp menp]||is with||n Ab titers 1:640[fndg imft aapp qnco]	2 trial[popg]||is in||high risk population of patients[fndg spco resa popg gngm podg qnco]	
further study[spco]||defined as||1:640 in treatment of COVID 19[hlca dsyn resa topp ftcn cnce qnco]	further study[spco]||defined as||1:640 in treatment[hlca dsyn resa topp ftcn cnce qnco]	study[cnce medd]||defined as||1:640 in treatment of COVID 19[hlca dsyn resa topp ftcn cnce qnco]	study[cnce medd]||defined as||1:640 in treatment[hlca dsyn resa topp ftcn cnce qnco]	
present study[mnob idcn fndg resa]||was supported by||UNC Health Foundation[cnce orgt idcn qlco]	present study[mnob idcn fndg resa]||was supported by||UNC Health Foundation at Chapel Hill with funding[mnob fndg spco inpr gngm topp qnco]	present study[mnob idcn fndg resa]||was supported by||UNC Health Foundation at University of North Carolina[mnob orgt inpr geoa]	present study[mnob idcn fndg resa]||was supported by||UNC Health Foundation at Chapel Hill with funding from North Carolina Coronavirus Relief Fund[fndg geoa dsyn virs qnco]	
laboratory assays[mnob lbpr lbtr irda qlco hcro ftcn imft aapp qnco]||were partially supported by||NIH NCI NIAID SeroNet Serocenter of Excellence Award U54 CA260543[mnob qlco hcro gngm mamm cnce]	laboratory assays[mnob lbpr lbtr irda qlco hcro ftcn imft aapp qnco]||were supported by||NIH NCI NIAID SeroNet Serocenter of Excellence Award U54 CA260543[mnob qlco hcro gngm mamm cnce]	laboratory assays[mnob lbpr lbtr irda qlco hcro ftcn imft aapp qnco]||were partially supported by||NIH NCI NIAID SeroNet Serocenter[mnob qlco hcro gngm mamm cnce]	laboratory assays[mnob lbpr lbtr irda qlco hcro ftcn imft aapp qnco]||were supported by||NIH NCI NIAID SeroNet Serocenter[mnob qlco hcro gngm mamm cnce]	
low antibody content CCP[fndg phsu qlco celc cnce imft aapp menp]||has emergency use authorization in||outpatient settings[hlca idcn podg qlco]	antibody content CCP[fndg phsu qlco celc cnce imft aapp menp]||has emergency use authorization in||outpatient settings[hlca idcn podg qlco]	low antibody content CCP[fndg phsu qlco celc cnce imft aapp menp]||has in||outpatient settings[hlca idcn podg qlco]	low antibody content CCP[fndg phsu qlco celc cnce imft aapp menp]||has||emergency use authorization from FDA[hcro inpr]	

One major limitation[fndg euka clas ocac inpr qlco resa ftcn qnco]||is in||interpreting published clinical trials[fndg euka clas ocac inpr qlco resa ftcn qnco]	
low antibody content CCP[fndg phsu qlco celc cnce imft aapp menp]||is more effective than||lower antibody content CCP[fndg phsu qlco celc cnce imft aapp menp]	low antibody content CCP[fndg phsu qlco celc cnce imft aapp menp]||is more effective than||antibody content CCP[fndg phsu qlco celc cnce imft aapp menp]	low antibody content CCP[fndg phsu qlco celc cnce imft aapp menp]||is effective than||lower antibody content CCP[fndg phsu qlco celc cnce imft aapp menp]	antibody content CCP[fndg phsu qlco celc cnce imft aapp menp]||is more effective than||lower antibody content CCP[fndg phsu qlco celc cnce imft aapp menp]	
We[fndg grpa qnco]||searched||PubMed articles[inpr]	We[fndg grpa qnco]||searched||PubMed articles published[inpr]	We[fndg grpa qnco]||searched||PubMed articles published between February 1 2020[ocac inpr qlco]	We[fndg grpa qnco]||using||terms[inpr tmco dsyn idcn orgf]	
We[inpr acty]||filtered by||selecting Clinical Trial[resa acty inpr]	We[inpr acty]||filtered respectively by||selecting Clinical Trial[resa acty inpr]	We[inpr acty]||filtered by||selecting Trial[resa acty inpr]	We[inpr acty]||filtered by||Clinical Trial[resa acty inpr]	
We[qlco]||identified||25 label studies in hospitalized patients[mnob resa lbpr podg]	We[qlco]||identified||25 open label studies in hospitalized patients[mnob resa lbpr podg]	We[qlco]||identified||25 open label studies[resa]	We[qlco]||identified||25 label studies in patients[mnob resa lbpr podg]	
Preliminary reports[inpr hlca tmco]||show||assays[lbpr qlco]	Preliminary reports[inpr hlca tmco]||show||assays used[lbpr qlco]	reports[inpr hlca tmco]||show||assays[lbpr qlco]	reports[inpr hlca tmco]||show||assays used[lbpr qlco]	
study[mnob resa]||deliberately infused||that[mnob resa]	study[mnob resa]||infused||that[mnob resa]	low antibody content CCP[fndg phsu qlco celc cnce imft aapp menp]||is with||n Ab 1:640[qnco]	
Post-hoc analyses[qlco fndg lbpr tmco]||showed||survival benefit[ftcn acty qnco]	analyses[ftcn idcn topp]||showed||survival benefit[ftcn acty qnco]	monoclonal antibody[phsu imft aapp]||suggesting||that[ftcn]	based therapies[ftcn idcn topp]||role in||improving outcomes of severe COVID 19[fndg inpr qlco dsyn ftcn socb]	
CCP[fndg inpr qlco idcn imft aapp qnco]||is with||high n Ab titer 1:640[fndg inpr qlco idcn imft aapp qnco]	
hazard ratio[qlco tmco qnco]||accounting as||competing event[evnt]	hazard ratio[qlco tmco qnco]||accounting for||death[ocac fndg orgf inpr]	hazard ratio[qlco tmco qnco]||accounting as||event[podg]	low antibody content CCP titer[fndg lbpr lbtr cnce imft aapp menp]||was||94 95 CI[lbpr qnco]	


CCP[fndg imft aapp]||recovery of||patients admitted with COVID 19[dsyn hlca]	CCP[fndg imft aapp]||expedites compared||very low antibody content CCP with n Ab 1:640 1:640[fndg phsu qlco celc cnce imft aapp menp]	CCP[fndg imft aapp]||recovery of||patients admitted with COVID[dsyn hlca]	CCP[fndg imft aapp]||expedites recovery compared||very low antibody content CCP with n Ab 1:640 1:640[fndg phsu qlco celc cnce imft aapp menp]	

policy guidance[clna topp inpr hlca]||raising||threshhold of n Ab 1:160[imft aapp qlco]	policy guidance[clna topp inpr hlca]||raising||threshhold[imft aapp qlco]	Further investigation[spco inpr hlca]||is with||n Ab 1:640[qnco]	

Abstract 35
People[popg]||are lagging behind in||national vaccination campaign[fndg geoa hlca spco popg gngm]	People[popg]||are lagging in||national vaccination campaign[fndg geoa hlca spco popg gngm]	People[popg]||are lagging behind in||vaccination campaign[fndg geoa hlca spco popg gngm]	People[popg]||are lagging in||vaccination campaign[fndg geoa hlca spco popg gngm]	
special population[popg]||be prioritized in||vaccination program[hlca]	population[popg]||be prioritized in||vaccination program[hlca]	special population[popg]||be||prioritized[hlca]	population[popg]||be||prioritized[hlca]	
we[inpr]||address||vaccine hesitation in special population[phsu imft aapp popg]	we[inpr]||address||vaccine hesitation in population[phsu imft aapp popg]	we[inpr]||assessed||safety[resa hcpp]	we[inpr]||assessed In||retrospective study[resa]	
4 study sites[hcro spco]||is in||China[geoa]	aged 40 years[fndg]||is In||retrospective study[resa]	
primary safety outcome[tmco qlco resa topp ftcn hcpp]||was incidence within||14 days after dose of vaccination[spco tmco topp clna qnco]	primary safety outcome[tmco qlco resa topp ftcn hcpp]||was incidence of||adverse events[ftcn inpr patf qnco]	safety outcome[tmco qlco resa topp ftcn hcpp]||was incidence within||14 days after dose of vaccination[spco tmco topp clna qnco]	safety outcome[tmco qlco resa topp ftcn hcpp]||was incidence of||adverse events[ftcn inpr patf qnco]	
primary safety outcome[tmco qlco resa topp ftcn hcpp]||was geometric mean titer GMT to||living SARS CoV 2 virus[fndg enzy inpr tmco qlco cnce aapp virs]	primary safety outcome[tmco qlco resa topp ftcn hcpp]||was geometric titer GMT to||living SARS CoV 2 virus[fndg enzy inpr tmco qlco cnce aapp virs]	primary safety outcome[tmco qlco resa topp ftcn hcpp]||was mean titer GMT to||living SARS CoV 2 virus[fndg enzy inpr tmco qlco cnce aapp virs]	primary safety outcome[tmco qlco resa topp ftcn hcpp]||was geometric mean titer GMT to||SARS CoV 2 virus[fndg enzy inpr tmco qlco cnce aapp virs]	
retrospective study[resa]||is registered with||ChiCTR.org.cn ChiCTR2200058281[dsyn prog hlca]	study[resa]||is registered with||ChiCTR.org.cn ChiCTR2200058281[dsyn prog hlca]	retrospective study[resa]||is||registered[dsyn prog hlca]	study[resa]||is||registered[dsyn prog hlca]	


significant difference[qlco idcn qnco]||was contributed by||fatigue in groups[inpr sosy popg idcn ftcn cnce]	significant difference[qlco idcn qnco]||was contributed by||fatigue[fndg inpr sosy acty]	significant difference[qlco idcn qnco]||was mainly contributed by||fatigue in groups[inpr sosy popg idcn ftcn cnce]	significant difference[qlco idcn qnco]||was mainly contributed by||fatigue[fndg inpr sosy acty]	




antibody GMTs[imft aapp irda]||decrease in||group[qlco popg idcn ftcn cnce qnco]	neutralizing antibody GMTs[imft aapp irda]||decrease in||group[qlco popg idcn ftcn cnce qnco]	
people[popg]||living with||chronic disease[tmco idcn qlco]	people[popg]||living with||disease[qnco tmco]	
overall trend[qlco inpr clna tmco]||was consistent||slightly different in subgroup[fndg clas inpr qlco dsyn virs]	overall trend[qlco inpr clna tmco]||was consistent||Although slightly different in subgroup[fndg clas inpr qlco dsyn virs]	immunogenicity[resa inpr]||is slightly different compared||that of special population[popg acty]	overall trend[qlco inpr clna tmco]||was consistent||Although different in subgroup[fndg clas inpr qlco dsyn virs]	
evidence[idcn]||address||vaccine hesitancy for seniors[phsu sosy idcn imft aapp]	evidence[idcn]||address||vaccine hesitancy for seniors living[phsu sosy idcn imft aapp]	evidence[idcn]||address||vaccine hesitancy[phsu sosy idcn imft aapp]	evidence[idcn]||address||vaccine hesitancy for seniors living with diseases[phsu sosy idcn imft aapp]	


Abstract 36
Data[ftcn fndg inpr]||are||limited[ftcn fndg inpr]	
study[mnob resa]||investigate||relationship between intraoperative EtCO2 level[clas geoa inpr tmco qlco idcn]	study[mnob resa]||investigate||relationship between intraoperative EtCO2 level in patients[clas geoa inpr tmco qlco idcn]	study[mnob resa]||was designed||investigate[ftcn]	study[mnob resa]||investigate||relationship between EtCO2 level[clas geoa inpr tmco qlco idcn]	
Kyoto University Hospital[hcro mnob]||conducted||retrospective cohort study[resa]	Kyoto University Hospital[hcro mnob]||conducted||retrospective cohort study involving[resa]	Kyoto University Hospital[hcro mnob]||conducted||cohort study[resa]	Kyoto University Hospital[hcro mnob]||conducted||cohort study involving[ftcn]	
Kyoto University Hospital[hcro mnob]||classified with||EtCO2[fndg qlco inpr qnco]	Kyoto University Hospital[hcro mnob]||classified with||mean EtCO2[qnco]	
time effect[qlco fndg tmco]||was evaluated by||measuring[qnco hlca qlco]	time effect[qlco fndg tmco]||was||whereas evaluated by measuring[qnco hlca qlco]	EtCO2 value[qnco]||was||below 35 mmHg[bacs lang dsyn gngm aapp qnco]	EtCO2 value[qnco]||was||when below 35 mmHg[bacs lang dsyn gngm aapp qnco]	
outcome[ftcn]||was||postoperative organ dysfunction[sosy tmco]	outcome[ftcn]||was||postoperative organ dysfunction defined[sosy tmco]	outcome[ftcn]||was||organ dysfunction defined as composite of at least one organ dysfunction[fndg inpr sosy qlco idcn cnce qnco]	outcome[ftcn]||was||organ dysfunction[phsf patf dsyn topp ftcn cnce ortf]	
1,428 34[fndg inpr qnco]||had||organ dysfunction[sosy tmco]	1,428 34[fndg inpr qnco]||had||postoperative organ dysfunction[sosy tmco]	
association[phpr socb menp qlco]||was found between||low EtCO2[qnco fndg inpr qlco]	association[phpr socb menp qlco]||increased||postoperative organ dysfunction adjusted risk ratio[fndg inpr sosy tmco ftcn qnco]	association[phpr socb menp qlco]||increased||postoperative organ dysfunction risk ratio[fndg inpr sosy tmco ftcn qnco]	association[phpr socb menp qlco]||increased||organ dysfunction adjusted risk ratio[fndg inpr sosy tmco ftcn qnco]	
organ dysfunction[bpoc patf tmco qlco dsyn ftcn cnce qnco]||adjusted||risk ratio[bpoc patf tmco qlco dsyn ftcn cnce qnco]	postoperative organ dysfunction[bpoc patf tmco qlco dsyn ftcn cnce qnco]||adjusted||risk ratio[bpoc patf tmco qlco dsyn ftcn cnce qnco]	


Abstract 37
Preconception care PCC[bacs hlca phsu neop topp cgab orch aapp celc]||is provision of||biomedical health interventions to women[clas hlca popg idcn ftcn clna]	Preconception care PCC[bacs hlca phsu neop topp cgab orch aapp celc]||is provision of||health interventions to women[clas hlca popg idcn ftcn clna]	Preconception care PCC[bacs hlca phsu neop topp cgab orch aapp celc]||is provision of||biomedical health interventions[clas hlca popg idcn ftcn clna]	Preconception care PCC[bacs hlca phsu neop topp cgab orch aapp celc]||is provision of||health interventions[clas hlca popg idcn ftcn clna]	
PCC[bacs phsu neop cgab topp orch aapp celc]||is||valuable[ftcn dsyn fndg]	
comprehensive preconception care provision[hlca inpr qlco ftcn clna]||is in||Kisumu County[fndg clas geoa acty spco inpr qlco gngm]	

data[inpr clna]||was collected In||cross-sectional study[resa]	data[inpr clna]||was collected in||health facilities[hcro ftcn mnob idcn]	data[inpr clna]||was collected in||health facilities using[hcro ftcn mnob idcn]	data[inpr clna]||was||In study collected in health facilities[hcro ftcn mnob idcn]	


significance[phsf idcn qnco]||was determined||quite low at 39[fndg inpr qnco qlco]	significance[phsf idcn qnco]||was determined||at P value quite low at 39[fndg inpr qnco qlco]	significance[phsf idcn qnco]||was determined||low at 39[fndg inpr qnco qlco]	significance[phsf idcn qnco]||was determined||quite low[fndg inpr qnco qlco]	
significance[phsf idcn qnco]||was observed||lower in primary level facilities KEPH level 2[mnob acty spco inpr tmco qlco topp blor]	significance[phsf idcn qnco]||was observed||to lower in primary level facilities KEPH level 2[mnob acty spco inpr tmco qlco topp blor]	significance[phsf idcn qnco]||was observed||lower in primary level facilities KEPH level 2 at 34[mnob acty spco inpr tmco qlco topp blor]	significance[phsf idcn qnco]||was observed||to lower in primary level facilities KEPH level 2 at 34[mnob acty spco inpr tmco qlco topp blor]	
service[ocac topp qnco]||was||HIV prevention[topp]	service[ocac topp qnco]||is with||highest implementation level[mnob fndg acty ocac idcn]	
service[inpr]||was||environmental risk exposure reduction at 13[inbe spco qlco inpo topp idcn npop cnce]	service[inpr]||was||environmental risk exposure reduction[inbe spco qlco inpo topp idcn npop cnce]	service[inpr]||is with||highest implementation level[mnob fndg acty ocac idcn]	service[inpr]||was||risk exposure reduction at 13[inbe spco qlco inpo topp idcn npop cnce]	
provision[idcn]||was||fragmented[ftcn anab qlco]	Provision[idcn]||was relatively low at||39[fndg inpr qnco qlco]	Provision[idcn]||was||relatively low[fndg inpr qnco qlco]	Provision[idcn]||was low at||39[fndg inpr qnco qlco]	
provision[idcn]||differed across||service levels[ocac mnob idcn qlco]	

Abstract 38
COVID 19 pandemic[dsyn]||resulted in||shift from traditional face to face care provision towards[hlca edac phsu inpr qlco idcn ftcn orch menp]	COVID 19 pandemic[dsyn]||resulted in||rapid shift from traditional face to face care provision towards[hlca edac phsu inpr qlco idcn ftcn orch menp]	COVID pandemic[dsyn]||resulted in||shift from traditional face to face care provision towards[hlca edac phsu inpr qlco idcn ftcn orch menp]	COVID 19 pandemic[dsyn]||resulted in||shift from traditional face care provision towards[hlca edac phsu inpr qlco idcn ftcn orch menp]	
substantial barriers[medd]||are||encountered[fndg hlca bhvr]	barriers[spco euka]||are||encountered[fndg hlca bhvr]	manner[fndg hlca bhvr]||have varied considerably across||settings[qlco]	manner[fndg hlca bhvr]||However have varied considerably across||settings[qlco]	

investigations[hlca]||evaluate||how different[menp qlco]	strategies[menp]||influence||implementation outcomes[ftcn acty]	investigations[hlca]||evaluate||different[menp qlco]	We[gngm idcn ftcn imft aapp]||aimed||to identify[menp qlco]	
Studies[lbpr qlco]||took||published between January 2010[ocac inpr qlco]	Studies[lbpr qlco]||focused on||strategies for achieving[menp]	Studies[lbpr qlco]||took||if published between January 2010[ocac inpr qlco]	systematic review[inpr]||was conducted with||five databases[inpr qnco]	
included studies[ftcn lbpr]||were assessed for||risk of bias[idcn bird acty cnce]	included studies[ftcn lbpr]||were assessed for||risk[idcn bird acty cnce]	included studies[ftcn lbpr]||were||assessed[idcn bird acty cnce]	
Data[medd idcn euka]||were||synthesised[ftcn]	

implementation strategies[cnce menp acty]||were||identified[fndg qlco]	

Using[ftcn]||appears||helpful method of supporting[lbpr inpr medd qlco ftcn cnce]	Using[ftcn]||appears||to helpful method of supporting[lbpr inpr medd qlco ftcn cnce]	Using[ftcn]||appears||method of supporting[lbpr inpr medd qlco ftcn cnce]	Using[ftcn]||appears||to method of supporting[lbpr inpr medd qlco ftcn cnce]	
Further research[spco resa]||test||impact of specific implementation strategies[acty inpr qlco gngm menp]	Further research[spco resa]||test||impact on implementation outcomes[ftcn acty]	Further research[spco resa]||test||impact of implementation strategies[acty inpr qlco gngm menp]	Further research[spco resa]||is needed||test[lbpr lbtr inpr blor ftcn]	

Abstract 39
We[tmco]||here examine||associations of polygenic risk score of antidepressant response[fndg phsu inpr orga menp]	We[tmco]||here examine||associations[menp]	We[tmco]||here examine||associations of risk score of antidepressant response[fndg phsu inpr orga menp]	We[tmco]||here examine||associations of published polygenic risk score of antidepressant response[fndg phsu inpr orga menp]	

We[inpr]||tested to||stratify between antidepressants[phsu lbpr]	We[inpr]||tested||utility of PRS AR[bacs fndg lbpr enzy dsyn gngm ftcn orgt aapp]	We[inpr]||also tested to||stratify between antidepressants[phsu lbpr]	We[inpr]||tested utility to||stratify between antidepressants[phsu lbpr]	

